


**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification<sup>7</sup> :</b> <b>C12N 15/82, 15/11</b>	<b>A2</b>	<b>(11) International Publication Number:</b> WO 00/63397 <b>(43) International Publication Date:</b> 26 October 2000 (26.10.00)
<b>(21) International Application Number:</b> PCT/EP00/03521 <b>(22) International Filing Date:</b> 17 April 2000 (17.04.00) <b>(30) Priority Data:</b> 09/294,022 20 April 1999 (20.04.99) US <b>(71) Applicant:</b> AVENTIS CROPS SCIENCE N.V. [BE/BE]; Jozef Plateastraat 22, B-9000 Gent (BE). <b>(72) Inventors:</b> MEULEWAETER, Frank; Wechaagstraat 73, B-9160 Eksaarde (BE). CORNELISSEN, Marc; Ellebogten 38, B-9070 Heusden (BE). JACOBS, John; Wilgenstraat 4, B-9820 Merelbeke (BE). VAN ELDIK, Gerben; Nekkersberglaan 41, B-9000 Gent (BE). METZLAFF, Michael; Irislaan 26, B-3080 Tervuren (BE).		<b>(81) Designated States:</b> AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>

**(54) Title:** METHODS AND MEANS FOR DELIVERING INHIBITORY RNA TO PLANTS AND APPLICATIONS THEREOFTobacco mosaic virus**(57) Abstract**

The invention provides methods and means for the identification of genes involved in the determination of a plant trait or for the identification encoded by a nucleic acid comprising a determined nucleotide sequence. The invention also provides kits comprising viral RNA vectors derived from satellite viruses and corresponding helper viruses for the introduction of inhibitory RNA into plant cells and plants.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LJ	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

WO 00/63397

PCT/EP00/03521

## Methods and means for delivering inhibitory RNA to plants and applications thereof

### Field of the invention.

5 This invention relates to the field of functional genomics in plants, more particularly it relates to methods for the further identification and isolation of a nucleic acid with a nucleotide sequence of interest in a collection of preselected nucleic acid sequences correlated with a particular trait, preferably an agronomical important trait, using a kit of viral RNA vectors  
10 which allow systemic spread of all components of the kit in a plant, wherein one of the viral RNA vectors comprises a library of gene-silencing constructs for the preselected nucleic acid sequences. The invention also relates to a method for modulating, preferably reducing, particularly eliminating the expression of a selected nucleic acid sequence, using the viral vector kit,  
15 whereby one of the vectors comprises a gene-silencing construct for the selected nucleic acid sequence. The latter method may be used for validating the function of a nucleic acid sequence whose expression is correlated with the presence or absence of a specific trait in plants, but with otherwise unknown function. Preferably, one of the viral RNA vector components of the  
20 kit is a vector derived from a satellite virus.

### Background art

25 The recent, rapid expansion of available nucleic acid sequence information has necessitated the development of methods for identifying the function of nucleic acid sequences, particularly transcribed nucleic acid sequences such as expressed sequence tags, with unknown function, in an efficient and labor-cost effective way.

30

To identify the role of sequenced nucleic acids from plants of unknown function it is necessary to produce or identify plants in which those nucleic acids are either structurally or functionally inactivated. Plants wherein

WO 00/63397

PCT/EP00/03521

2

predetermined nucleic acid sequences are structurally inactivated can be generated using recombination technologies such as homologous recombination as described by Kempin et al. (1997) or using specific technologies such as the use of mixed duplex oligonucleotides (chimeraplasts) to generate specific mutations (as described in WO-96/22364 and WO 99/07865) . Alternatively, plants with a mutation in a predetermined nucleotide sequence can be identified by screening a saturated mutant library, such as but not limited to a T-DNA insertion library or a transposon insertion library (see e.g. Pereira and Aerts, 1998). These methodologies all require the generation of a large number of permanently altered plants, and thus are less amenable for application in high throughput methods. Moreover, the recovery of plants with recessive mutations in essential genes requires time-consuming breeding to maintain the plants in heterozygous state. Maintenance of dominant lethal mutations in essential genes is virtually impossible.

Plants with functionally inactivated predetermined nucleotide sequences can be generated in a straightforward way using methodologies wherein inhibitory RNA is generated, such as antisense or sense RNA.

20

The use of inhibitory RNA to reduce or abolish gene expression, also known as gene silencing, is well established in the art and is the subject of several reviews (e.g Baulcombe 1996, Stam et al. 1997, Depicker and Van Montagu, 1997). Several patent applications relate to the practical exploitation of gene silencing.

25

US 5,190,131 and EP 0 467 349 A1 describe methods and means to regulate or inhibit gene expression in a cell by incorporating into or associating with the genetic material of the cell a non-native nucleic acid sequence which is transcribed to produce an mRNA which is complementary to and capable of binding to the mRNA produced by the genetic material of that cell.

30

WO 00/63397

PCT/EP00/03521

3

EP 0 240 208 describes a method to regulate expression of genes encoded for in plant cell genomes, achieved by integration of a gene under the transcriptional control of a promoter which is functional in the host and in which the transcribed strand of DNA is complementary to the strand of DNA  
5 that is transcribed from the endogenous gene(s) one wishes to regulate.

EP 0 223 399 A1 describes methods to effect useful somatic changes in plants by causing the transcription in the plant cells of negative RNA strands which are substantially complementary to a target RNA strand. The target  
10 RNA strand can be a mRNA transcript created in gene expression, a viral RNA, or other RNA present in the plant cells. The negative RNA strand is complementary to at least a portion of the target RNA strand to inhibit its activity *in vivo*.

15 EP 0 647 715 A1 and US patents 5, 034,323, 5,231,020 and 5,283,184 describe methods and means for producing plants exhibiting desired phenotypic traits, by selecting transgenotes that comprise a DNA segment operably linked to a promoter, wherein transcription products of the segment are substantially homologous to corresponding transcripts of endogenous  
20 genes, particularly endogenous flavonoid biosynthetic pathway genes.

WO 93/23551 describes methods and means for the inhibition of two or more target genes, which comprise introducing into the plant a single control gene which has distinct DNA regions homologous to each of the target genes and a  
25 promoter operative in plants adapted to transcribe from such distinct regions RNA that inhibits expression of each of the target genes.

A major disadvantage of these technologies, which hampers the exploitation thereof in high throughput gene function discovery methods, is the intrinsic  
30 unpredictability and low occurrence of the gene silencing phenomenon.

Recently, Waterhouse et al. (1998) have described methods and means to make gene silencing in plants more efficient and predictable, by simultaneous

WO 00/63397

PCT/EP00/03521

4

expression of both sense and antisense constructs in cells of one plant. The sense and antisense nucleic acids may be in the same transcriptional unit, so that a single RNA transcript that has self-complementarity is generated upon transcription.

5

Hamilton et al. (1998) describe improved silencing e.g. of tomato ACC-oxidase gene expression using a sense RNA containing two additional upstream inverted copies of its 5' untranslated region.

10 WO 98/53083 describes constructs and methods for enhancing the inhibition of a target gene within an organism, involving the insertion into the gene silencing vector of an inverted repeat of all or part of a polynucleotide region within the vector.

15 It should be clear however, that the use of inhibitory RNA as a tool in reversed genetics analysis of gene function via high throughput methods, whereby the inhibitory RNA is generated from gene-silencing constructs which are stably integrated in the genome of transgenic plants, suffers from the same drawbacks as the methods wherein the nucleotide sequences are structurally  
20 inactivated.

EP 0 194 809 and US 5,500,360 suggest the use of viral RNA vectors to produce regulatory RNA such as anti-sense RNA.

25 Initial exploration of the use of viral vectors to deliver inhibitory RNA into cells of plants has been described by Chapman (1991). In this publication, gene silencing constructs comprising nucleotide sequences complementary to the translated region of the GUS gene on a PVX derived viral vector were described. The experiments however, remained inconclusive as to whether  
30 gene silencing could be provoked using viral vectors for the production of inhibitory RNA.

WO 00/63397

PCT/EP00/03521

5

WO 93/03161 is directed toward recombinant plant viral nucleic acids and to hosts infected thereby. The non-native nucleic acid sequence which is transcribed may be transcribed as an RNA which is capable of regulating the expression of a phenotypic trait by an anti-sense mechanism.

5

English et al., 1996 describe the suppression of the accumulation of a viral vector comprising a foreign nucleotide sequence in transgenic plants exhibiting silencing of nuclear genes comprising the same foreign nucleotide sequences, thus linking gene silencing and viral vectors, albeit in a reverse way as envisioned here.

10

Kumagai et al. 1995 (PNAS 92, 1679-1683) described the inhibition of phytoene desaturase gene by viral delivery of antisense RNA.

15

WO 95/34668 suggests the use of genetic constructs based on RNA viruses which replicate in the cytoplasm of cells to provide inhibitory RNA, either antisense or co-suppressor (sense) RNA.

20

Baulcombe et al. (1998) and Ruiz et al. (1998) describe virus-induced gene silencing of the endogenous phytoene desaturase gene (PDS) or of a green fluorescent protein transgene (GFP) in plants, using potato virus X derived vectors carrying inserts homologous to PDS and GFP, respectively. The authors further suggested that virus-induced gene silencing may develop into a novel assay of gene function, by introducing a fragment of the genome of a viral vector and inferring the function of the gene from the symptoms of the infected plants exhibiting gene silencing.

25

The described methods for identification of the function of a gene with known nucleotide sequence however, have drawbacks and limitations. In the first place, the applicability of the mentioned viral RNA vector based gene silencing methods on larger scale is in practice limited to the identification of genes with essential functions or genes with macroscopically visible phenotypes. Secondly, all methods employ viral vectors which are capable of

30

WO 00/63397

PCT/EP00/03521

6

autonomous replication in plant cells and cell-to-cell movement , whereby care has to be taken not to inactivate the essential functions required for these functions. This may particularly be a disadvantage when tailoring these methods to the needs of particular plants, such as crop plants, by developing  
5 new viral vectors more apt for replication and systemic spread in the plants.

The prior art is thus deficient in the lack of efficient methods for large scale identification of the function of nucleic acids with known nucleotide sequence, or for the isolation of the genes of interest from a pool of genes with known  
10 nucleotide sequence, but unknown function.

#### Brief Description of the figures

15 Figure 1 is a schematic representation of the viral RNA vectors used in the Examples. MP: movement protein; CP: coat protein; OAS: origin of assembly. The open reading frames are indicated by boxes. Each original viral genome is characterized by a specific pattern.

20 ■■■ : tobacco mosaic virus; ■■■ tobacco necrosis virus; ■■■ satellite tobacco mosaic virus; ■■■ satellite tobacco necrosis virus.

#### Summary of the invention

25 The invention provides a method for isolating genes involved in the determination of a trait or a phenotype of a plant species, comprising identifying a set of nucleic acids sequences of genes, whose expression is correlated with a trait of interest; creating a library of gene silencing constructs targeted or adapted to the nucleotide sequence of the identified nucleic acids in a viral RNA vector which is capable of replication inside plant cells and  
30 optionally, movement between plant cells of a plant; infecting a collection of individual plants of the same plant species with the library of gene silencing constructs whereby each plant is infected with at least one member of the library; identifying a plant wherein the trait or phenotype is altered using an assay adapted to that trait or phenotype; and isolating the gene involved in the  
35 determination of the trait or phenotype in the plant species, from the library, based on the nucleotide sequence to which the gene silencing construct in the



WO 00/63397

PCT/EP00/03521

7

identified plant was targeted. Preferably the viral RNA vector is capable of autonomous replication inside plant cells and optionally autonomous movement between plant cells and particularly the viral RNA vector is derived from cowpea mosaic virus.

5

Alternatively, the viral RNA vector, is derived from a satellite RNA virus, preferably satellite tobacco mosaic virus or satellite tobacco necrosis virus, particularly it further comprises an origin of assembly of tobacco mosaic virus, and is capable of replication inside plant cells and optionally movement  
10 between plant cells when the required factors are supplemented *in trans*, preferably by infection with a helper virus, preferably tobacco mosaic virus or a helper virus which is derived from tobacco necrosis virus and comprises a gene encoding a coat protein gene of tobacco mosaic virus, and optionally, a movement protein of tobacco mosaic virus.

15

Gene-silencing constructs comprised within the viral RNA vector may comprise antisense RNA or sense RNA, preferably they may comprise an inverted repeat. Particularly the gene-silencing constructs comprise complementary stretch of at least 50, preferably at least 100 nucleotides of  
20 sense and antisense RNA. Especially preferred are gene-silencing constructs comprising at least two copies of part of the nucleotide sequences of the collection of nucleic acids, the copies being in inverted repeat.

25

It is another object of the invention to provide a method for the isolation or selection of a nucleic acid with a specific function from a collection of nucleic acids, wherein the collection of nucleic acids is characterized by the fact that variation in the expression pattern of the nucleic acids is correlated with variation in a trait or phenotype of a plant harboring the nucleic acids comprising the steps of creating a library of gene silencing constructs targeted  
30 or adapted to the nucleotide sequence of the identified nucleic acids in a viral RNA vector which is capable of replication inside and optionally movement between plant cells; infecting a collection of plants with the library of gene silencing constructs, whereby each plant is infected with one member of the

WO 00/63397

PCT/EP00/03521

8

library; identifying plants with altered trait or phenotype using an assay adapted to the trait or phenotype under investigation; and optionally isolating the nucleic acid with the specific function from the identified plant with altered trait or phenotype.

5

It is yet another object of the invention to provide a method for determining the function encoded by a nucleic acid comprising a known nucleotide sequence in a plant, comprising the steps of providing a viral RNA vector derived from a satellite RNA virus, comprising a gene-silencing construct targeted to a gene  
10 comprising the known nucleotide sequence; infecting or inoculating the plant with the chimaeric viral RNA vector and a corresponding helper virus or helper virus RNA; and identifying an altered trait or phenotype of the co-infected plant.

15 The invention further provides a method for isolating essential genes from a plant, comprising creating a library of random gene-silencing constructs, preferably by cloning random DNA fragments of the plant or by cloning random cDNA fragments, particularly duplicated cDNA fragments in inverted repeat in a cDNA copy of the viral RNA vector derived from a satellite RNA  
20 virus, preferably STMV or STNV, particularly a viral RNA vector comprising an origin of assembly of TMV; infecting a plant with individual members of the library and with a corresponding helper virus, preferably tobacco mosaic virus or a helper virus derived from tobacco necrosis virus and comprising the coat protein of tobacco mosaic virus and optionally the movement protein;  
25 identifying plants developing gene-silencing-construct-associated necrosis and optionally isolating the viral RNA vector from the necrotized tissue.

It is yet another object of the invention to provide a method for introduction of inhibitory RNA, preferably sense or antisense RNA, particularly inhibitory RNA  
30 comprising an inverted repeat, especially inhibitory RNA comprising a complementary stretch of at least 50, preferably at least 100 nucleotides of sense and antisense RNA, into plant cells, preferably into the cytoplasm of plant cells, comprising introducing into a plant cell, a viral RNA vector

WO 00/63397

PCT/EP00/03521

9

comprising the inhibitory RNA or comprising a chimeric nucleic acid which when transcribed yields the inhibitory RNA, wherein the viral RNA vector is derived from a satellite RNA virus, preferably STMV or STNV, particularly a STMV - derived or STNV derived RNA vector comprising an origin of assembly from tobacco mosaic virus; and introducing into the same plant cell, a corresponding helper virus, preferably tobacco mosaic virus or a chimaeric helper virus derived from tobacco necrosis virus and comprising a coat protein gene of tobacco mosaic virus and optionally, a movement protein encoding gene of tobacco mosaic virus.

10

The invention further provides a kit for introduction of inhibitory RNA, preferably sense or antisense RNA, particularly inhibitory RNA comprising an inverted repeat, especially inhibitory RNA comprising a complementary stretch of at least 50, preferably at least 100 nucleotides of sense and antisense RNA in the cytoplasm of a plant cell comprising 1) a viral RNA vector derived from a satellite RNA virus, comprising the inhibitory RNA or which comprise a chimeric nucleic acid which when transcribed yields the inhibitory RNA; and 2) a corresponding helper virus.

20 A particularly preferred kit comprises 1) a viral RNA vector derived from a satellite tobacco mosaic virus, comprising an origin of assembly of tobacco mosaic virus, further comprising or encoding the inhibitory RNA; and 2) a corresponding helper virus derived from a tobacco mosaic virus.

25 Another particularly preferred kit comprises 1) a viral RNA vector derived from satellite tobacco necrosis virus, especially STNV-2 or STNV-C and comprising an origin of assembly of tobacco mosaic virus further comprising or encoding the inhibitory RNA; and 2) a corresponding helper virus derived from tobacco necrosis virus, particularly TNV-A or TNV-D, which comprises a coat protein gene of tobacco mosaic virus and optionally a movement protein gene of tobacco mosaic virus.

30

WO 00/63397

PCT/EP00/03521

10

**Detailed description of preferred embodiments.**

The following definitions apply throughout this application, unless otherwise specified.

- 5 As used herein "comprising" is to be interpreted as specifying the presence of the stated features, integers, steps or components as referred to, but does not preclude the presence or addition of one or more features, integers, steps or components, or groups thereof. Thus, e.g., a nucleic acid or protein comprising a sequence of nucleotides or amino acids, may comprise more  
10 nucleotides or amino acids than the actually cited ones, i.e., be embedded in a larger nucleic acid or protein. A chimeric gene comprising a DNA region which is functionally or structurally defined, may comprise additional DNA regions etc.
- 15 As used herein, "a trait of a plant" indicates a phenotype which is the combined result of the coordinated expression of a number of genes. Typical traits include yield, heterosis, drought-resistance, stress-resistance, high or low temperature-resistance, vigor, seed yield, plant habitat, architecture etc. Typically, a trait of a plant is named after its intended appearance.
- 20 A used herein a "phenotype" of a plant refers to any quantitative or qualitative characteristic of that plant, be it morphological (including macroscopic and microscopic characteristics), biochemical (including the presence, absence or concentration of particular metabolites or molecules) functional or other.
- 25 The term "gene" means any DNA or RNA fragment comprising a region (the "transcribed region") which is transcribed into a RNA molecule (e.g., a mRNA) in a cell, operably linked to suitable regulatory regions, e.g., a plant-expressible promoter. A gene may thus comprise several operably linked  
30 fragments such as a promoter, a 5' leader sequence, a coding region, and a 3' region comprising a polyadenylation site. A plant gene endogenous to a particular plant species or virus (endogenous plant or virus gene) is a gene which is naturally found in that plant species or virus, or which can be introduced in that plant species by breeding techniques such as conventional  
35 breeding techniques. A chimeric gene is any gene which is not normally found

WO 00/63397

PCT/EP00/03521

11

in a plant species or, alternatively, any gene in which the promoter is not associated in nature with part or all of the transcribed DNA region or with at least one other regulatory region of the gene.

- 5 The term "expression of a gene" refers to the process wherein a DNA or RNA region which is operably linked to appropriate regulatory regions, particularly to a promoter, is transcribed into an RNA which is biologically active i.e., which is either capable of interaction with another nucleic acid or which is capable of being translated into a biologically active polypeptide or protein. A  
10 gene is said to encode an RNA when the end product of the expression of the gene is biologically active RNA, such as e.g. an antisense RNA, a ribozyme or a replicative intermediate. A gene is said to encode a protein when the end product of the expression of the gene is a biologically active protein or polypeptide. In addition to the above defined elements, a gene may further  
15 comprise elements for cap-independent translation such as an internal ribosome entry sequence or the first and second translation enhancing elements as defined in WO 97/49814.

20 As used herein the terms "gene-silencing" or "inhibitory" are not to be interpreted as meaning a complete abolishing of the expression of the target gene(s) but also includes any reduction in expression, measured either as a reduction in transcription and/or translation, as a reduction in the accumulation of transcripts or translation products such as proteins, or as a reduction in the phenotypic expression of the target gene.

25

The term "reduction of phenotypic expression" refers to the comparison of the phenotypic expression of the nucleic acid of interest in the eukaryotic cell in the presence of the inhibitory RNA or gene-silencing constructs of the invention, to the phenotypic expression of the nucleic acid of interest in a  
30 similar eukaryotic cell in the absence of the inhibitory RNA or gene-silencing constructs of the invention. The phenotypic expression in the presence of the inhibitory RNA of the invention should thus be lower than the phenotypic expression in absence thereof, preferably be only about 25%, particularly only

WO 00/63397

PCT/EP00/03521

12

about 10%, more particularly only about 5% of the phenotypic expression in absence of the inhibitory RNA, especially the phenotypic expression should be completely inhibited for all practical purposes by the presence of the inhibitory RNA or the gene-silencing construct encoding such an RNA.

5

A reduction of phenotypic expression of a nucleic acid where the phenotype is a qualitative trait means that in the presence of the inhibitory RNA, the phenotypic trait switches to a different discrete state when compared to a situation in which such inhibitory RNA is absent. A reduction of phenotypic  
10 expression of a nucleic acid may thus a.o. be measured as a reduction in transcription of (part of) that nucleic acid or reduction in the level of transcript, a reduction in translation of (part of ) that nucleic acid or reduction in the level of translation products, or a reduction of the effect the presence of the transcribed RNA(s) or translated polypeptide(s) have on the eucaryotic cell or  
15 the organism, and will ultimately lead to altered phenotypes. It is clear that the reduction in phenotypic expression of a nucleic acid of interest, may be accompanied by or correlated to an increase in a phenotype or trait.

In one embodiment of the invention, a method is provided to identify and  
20 isolate genes involved in the determination of a trait or a phenotype of a plant. To this end, nucleic acid sequences are identified whose expression is correlated with the trait and/or phenotype of interest. Methods and means are available in the art for the almost simultaneous identification and/or isolation of a large number, if not the predominant part, of nucleotide sequences whose  
25 expression, particularly whose transcription, is influenced subsequent to a stimulus corresponding to the trait to be investigated, in comparison with expression of these nucleotide sequences in a control plant. Such methods include but are not limited to differential display methods, such as the gel - based RNA differential display methods described by (Prahasar et al. 1996)  
30 As a result of these methods, a collection of at least partially characterized nucleotide sequences with altered expression in response to a particular stimulus is identified. Typically, however, the application of such methods does not allow to discriminate between genes whose altered expression is

WO 00/63397

PCT/EP00/03521

13

directly caused by the stimulus, and those who are further downstream in the chain of events and are only indirectly influenced by the stimulus and a further selection amongst the obtained collection of nucleotide sequences will be required. Even less do these methods allow to predict whether the inverse relationship also holds, i.e. whether influencing the expression of genes with particular nucleotide sequences, identified in the above mentioned way, also influences the trait of interest. A further validation of the obtained sequences is thus required, and preferably one which immediately verifies the above mentioned inverse relationship. To achieve this goal in a efficient and cost-effective way, a library of gene-silencing constructs may be created in a viral RNA vector which is capable of replication inside plant cells and movement between cells of a plant, so as to assure an efficient systemic spread within a plant which has been infected with a clone of such a library. The created library of gene-silencing constructs comprised within a viral RNA vector is then used to infect a representative number of plants in such a way that at each plant is infected by at least one member (one clone) of the library. The infected plants can then be analyzed to identify those plants which exhibit alterations in the trait under investigation, using an assay which is adapted to the trait under investigation. It is clear that this fine-tuning of assay and trait under investigation may be an important advantage over the existing methods for high throughput analysis, particularly when analyzing traits and/or phenotypes which do not result in macroscopically visible alterations, such as but not limited to modifications in specific metabolic pathways or alterations which are only detectable under specific conditions (e.g. heat, stress, drought-tolerance, pathogen-infection, application of specific herbicides or insecticides etc.).

The subset of nucleic acid sequences may also be identified on the basis of the presence of a particular signature characteristic of a class of proteins, such as but not limited to a kinase-specific domain, a binding motif etc.

The gene-silencing construct may then be isolated from the library or from the plant exhibiting the altered trait or phenotype, and be used to isolate the

WO 00/63397

PCT/EP00/03521

14

corresponding gene based on the nucleotide sequence towards which the gene silencing construct was targeted.

In a preferred embodiment, the viral RNA vector is capable of autonomous replication inside plant cells and autonomous movement between plant cells. Such viral RNA vectors are known in the art and may be based on Potato Virus X as described e.g. in WO 93/03161, WO95/34668, Ruiz et al. (1998)

In a particularly preferred embodiment, the used viral RNA vector is derived from cowpea mosaic virus. Wellink et al. (1998) have described the use of a viral vector derived from this RNA virus for the expression of GFP in plants and demonstrated that the virus and RNA vectors derived thereof have an excellent capacity for spreading throughout an infected plant, particularly *Nicotiana benthamiana*. CPMV is an icosahedral virus with a bipartite RNA genome, consisting of a longer and a shorter RNA. Wellinck et al. have demonstrated that it is possible to incorporate extra genetic information in the shorter RNA, by inserting the GFP coding region in frame into the viral encoded polyprotein. For the purpose of the herein described methods, it is preferred that the inhibitory RNA encoding nucleic acid be inserted downstream of the polyprotein encoding open reading frame.

The inventors have obtained for the first time indications that gene-silencing may be obtained in plant cells such as protoplasts, using a viral vector derived from a satellite virus comprising a  $\beta$ -1,3-glucanase coding region, in a co-infection experiment with a helper virus of the satellite virus

In another preferred embodiment, the viral RNA vector is capable of replication and cell-to-cell movement, only when the required functions are provided *in trans*. Particularly preferred, is the use of a satellite virus derived RNA vector, which can replicate in plant cells and spread throughout the plant, when a corresponding helper virus is present.



WO 00/63397

PCT/EP00/03521

15

As used herein, "a satellite virus" indicates an RNA virus, preferably a single stranded RNA virus, the RNA genome of which is capable of replicating in a plant cell and being encapsidated by coat protein molecules to form a virus particle or virion, only when provided externally with any number of required essential functions therefor. By "externally provided" is meant that such functions are not encoded by the satellite viral genome. Satellite viruses thus depend upon external provision of essential functions, and may lack the capacity to encode functional replicase, movement protein, or other essential functions required to complete their life cycle inside a plant cell. In a natural situation, such essential functions are usually provided by an autonomously replicating virus or so-called helper virus.

Satellite viruses useful for the present invention may include wild type isolates, but also encompassed by this definition are variants which result in reduced or minimal symptoms when infected on a host plant, particularly when co-inoculated with a corresponding helper virus. The definition also includes synthetic satellite viruses such as defective viruses and chimeric satellite viruses.

A "viral RNA vector derived from a satellite virus" should at least include cis elements from a satellite virus which are recognized by an externally provided replicase, and an origin of assembly allowing encapsidation by the provided coat protein. Preferably, the viral RNA vector does not comprise a gene encoding a functional coat protein, particularly it does not comprise the nucleotide sequence which is essentially similar to the nucleotide sequence encoding a coat protein gene. Particularly preferred are viral RNA vectors comprising an origin of assembly recognized by coat protein molecules from a rod-shaped virus, such as tobacco mosaic virus, since rod-shaped viruses do not exhibit the spatial constraints imposed on the size of genome by icosahedral viruses, thus allowing a larger number of additional nucleotides to be incorporated in the viral vector. Conveniently, the viral RNA vector comprises a number of unique or low-occurrence restriction recognition sites.

WO 00/63397

PCT/EP00/03521

16

The use of viral RNA vectors derived from a satellite virus, additionally solves problems associated with the use of viral RNA vectors, such as reducing the size of the vectors, increasing versatility etc.

- 5 Particularly suited for the invention are viral RNA vectors derived from satellite tobacco mosaic virus comprising the origin of assembly (OAS) from TMV, preferably comprising the nucleotide sequence of SEQ ID No 2 from the nucleotide at position 5443 to the nucleotide at position 5518 or the nucleotide of SEQ ID No 5 from the nucleotide at position 5430 to the nucleotide at  
10 position 5505 (such as the nucleotide sequence of SEQ ID No 12) and wherein the coat protein encoding gene has been deleted. Also particularly suited for the invention are viral RNA vectors derived from satellite necrosis vector strain comprising the OAS from TMV and wherein most of the coat protein gene has been deleted. Non-limiting examples of viral RNA vectors,  
15 suitable for the invention are described hereinafter.

- "A corresponding helper virus" as used herein, indicates those RNA viruses, preferably single stranded RNA viruses, which can supply the satellite virus or the derived viral RNA vector with the functions required *in trans* by that  
20 satellite virus or the derived viral RNA vector, to allow it to replicate in the cytoplasm of plant cells, and spread throughout an infected plant. Typically, corresponding helper viruses will provide the satellite virus or the vector derived thereof with a replicase (RNA dependent RNA polymerase) which recognizes the *cis* sequences present on the satellite virus RNA, and will  
25 allow replication of the satellite virus genome or the derived vector. Other proteins which may typically be provided by the helper virus are movement proteins, allowing inter alia, the plasmodesmata-mediated spread of viral particles from cell to cell. For satellite viruses or viral RNA vectors derived thereof which lack a functional coat protein encoding gene, corresponding  
30 helper viruses may also provide a functional coat protein. Preferably, the corresponding helper virus will be capable of autonomous systemic spread in an infected plant. However, such a systemic spread seems not to be a prerequisite for efficient gene silencing. Functions required *in trans* for one

WO 00/63397

PCT/EP00/03521

17

particular viral RNA vector may be supplied *in trans* by different corresponding helper viruses.

It is clear that the corresponding helper viruses may be wild type isolates of  
5 RNA viruses, preferably single-stranded RNA viruses such as the  
tobamoviruses or necroviruses. Particularly preferred are rod-shaped RNA  
viruses such as tobamoviruses including tobacco mosaic virus and the related  
tobamoviruses such as ribgrass mosaic virus, turnip vein clearing virus,  
chinese rape mosaic virus, oilseed rape mosaic virus.

10

When TMV can be used as a helper virus, it can also be replaced by one of  
the closely related tobamoviruses mentioned above, particularly when using  
the viral vectors in particular plant species.

15 Also encompassed by the methods and means of the invention are variants of  
such wild type isolates, preferably variants or mutants which develop minimal  
symptoms when inoculated on host plants or when co-infected with a  
corresponding satellite virus or RNA vector derived thereof. Further preferred  
helper viruses may be variants or mutants of wild type isolates which have an  
20 extended host range such as tobamoviruses which can replicate and spread  
in corn or brassicae.

However, corresponding helper viruses may also be chimeric or hybrid  
viruses, wherein part of the viral genome has been replaced by a foreign  
25 nucleic acid, particularly wherein part of the viral genome has been replaced  
by a nucleic acid derived from another viral genome, preferably a part  
comprising a nucleotide sequence encoding a movement protein, or a part  
comprising a nucleotide sequence encoding a coat protein. E.g. when using a  
necrovirus such as TNV, it may be advantageous to insert a movement  
30 protein encoding region, preferably a movement protein derived from a  
tobamovirus such as TMV, particularly the nucleotide sequence of SEQ ID No  
2 from the nucleotide at position 4903 to the nucleotide at position 5709, so as  
to ensure spreading of the viral particles beyond the infected leaf. However,

WO 00/63397

PCT/EP00/03521

18

spreading of the helper virus or the viral RNA vector is not essential for efficient inactivation of expression of the target genes throughout the plant, as was found by the inventors. Also when using e.g. a necrovirus such as TNV, it may be further advantageous to replace the coat protein coding region of the  
5 necrovirus by a coat protein coding region of a rod-shaped virus, such as TMV, particularly the nucleotide sequence of SEQ ID No 2 from the nucleotide at position 5712 to the nucleotide at position 6191. It goes without saying that an appropriate origin of assembly for the substituted coat protein has to be incorporated in the genome of the chimaeric helper virus. In the  
10 above described example however, the OAS of TMV is conveniently located within the movement protein coding region. Non-limiting examples of corresponding helper viruses will be described hereinafter.

It should be clear that whenever it is stated that plants are co-infected or  
15 infected with a viral RNA vector and a corresponding helper virus, it is equal whether the helper virus is inoculated before, after or simultaneous with the viral RNA vector, provided however that there is a reasonable time limit between infection of the viral RNA vector or the corresponding helper virus.

20 Alternatively, the required functions *in trans* for the replication and movement of the viral RNA vector may be provided from the expression of chimeric genes, encoding a replicase (RNA dependent RNA polymerase) and/or a movement protein and/or a functional coat protein, integrated in the genome of the test plants.

25

Preferred kits to deliver inhibitory RNA or gene-silencing constructs to plant cells to be used in the herein disclosed methods comprise a viral RNA vector derived from a satellite RNA virus, particularly from satellite tobacco necrosis vector (STNV) or satellite tobacco mosaic virus (STMV) and a corresponding  
30 helper virus, particularly a rod-shaped corresponding helper virus, wherein the viral RNA vector comprises a gene-silencing construct.

WO 00/63397

PCT/EP00/03521

19

In a preferred embodiment the kit comprises a viral RNA vector derived from satellite tobacco necrosis vector, preferably comprising the cis-elements required for replication, particularly comprising the nucleotide sequence of SEQ ID No 3 from the nucleotide at position 1 to the nucleotide at position 32  
5 and the nucleotide sequence of SEQ ID No 3 from the nucleotide at position 738 to the nucleotide at position 1245, wherein an origin of assembly of tobacco mosaic virus has been inserted, preferably comprising the nucleotide sequence of SEQ ID No 2 from the nucleotide at position 5443 to the nucleotide at position 5518 or comprising the nucleotide sequence of SEQ ID  
10 No 5 from the nucleotide at position 5430 to the nucleotide at position 5505, or comprising the nucleotide sequence of SEQ ID No 12 and wherein said helper virus is derived from tobacco necrosis virus, preferably with a nucleotide sequence of SEQ ID No 1, and comprises a gene encoding the movement protein of tobacco mosaic virus, preferably with the nucleotide  
15 sequence of SEQ ID No 2 from the nucleotide at position 4903 to the nucleotide at position 5709 or with the nucleotide sequence of SEQ ID No 15 from the nucleotide at position 479 to the nucleotide at position 1285 and a gene encoding the coat protein of tobacco mosaic virus, preferably with the nucleotide sequence of SEQ ID No 2 from the nucleotide at position 5712 to  
20 the nucleotide at position 6191 or with the nucleotide sequence of SEQ ID No 15 from the nucleotide at position 1288 to the nucleotide at position 1767.

Preferred combinations are those kits wherein the viral RNA vector is derived from STNV-1 or STNV-2 strains (as disclosed by Ysebaert et al. 1980;  
25 Genbank Accession number M10388 or Danthinne et al., 1991 Genbank Accession M64479) and the helper virus is TNV-A (Meulewaeter et al 1990, SEQ ID No 1). Other preferred combinations are those kits wherein the viral RNA vector is derived from STNV-C (Bringloe et al. (1998); Genbank Accession Nr AJ000898) and the corresponding helper virus is TNV-D (Courtts  
30 et al. (1991); Genbank Accession Nr D00942).

In another particularly preferred embodiment the kit comprises a viral RNA vector derived from satellite tobacco mosaic virus, preferably comprising the

WO 00/63397

PCT/EP00/03521

20

cis-elements required for replication, particularly comprising the nucleotide sequence of SEQ ID No 4 from the nucleotide at position 1 to the nucleotide at position 197 and the nucleotide sequence of SEQ ID No 4 from the nucleotide at position 604 to the nucleotide at position 1058 or comprising the nucleotide sequence of SEQ ID No 13 and the nucleotide sequence of SEQ ID No 14; and further comprising an origin of assembly of tobacco mosaic virus, preferably comprising the nucleotide sequence of SEQ ID No 2 from the nucleotide at position 5443 to the nucleotide at position 5518 or comprising the nucleotide sequence of SEQ ID No 5 from the nucleotide at position 5430 to the nucleotide at position 5505 or comprising the nucleotide sequence from SEQ ID No 12, and wherein said corresponding helper virus is a tobacco mosaic virus, particularly TMV-U1 (SEQ ID No 2) or TMV-U2 (SEQ ID No 5).

It will be clear to the person skilled in the art that viral RNA vectors may be generated conveniently by *in vitro* transcription methods from cDNA copies of the viral RNA. Likewise, infectious viral RNA for the corresponding helper viruses may be generated from cDNA copies of their genome. Libraries, viral vectors and corresponding helper viruses may also be maintained by replication in plant cells.

Methods to infect or inoculate plants and plant cells with viral RNA vectors, helper viruses and libraries comprised within viral RNA vectors are well within the realm of the person skilled in the art and may be performed according to the methods described in Walkey (1985).

In one embodiment of the methods of the invention, plants are inoculated, e.g. with a solution containing the libraries of gene-silencing constructs in a viral vector, or with a solution containing a mixture of gene-silencing constructs in a viral vector and corresponding helper virus. The solution may further contain additional compounds to improve inoculation and infection of the plants, such as, but not limited to abrasives, adherents, tensio-active products and the like.

WO 00/63397

PCT/EP00/03521

21

Plants may be infected during different developmental stages, in order to maximize the phenotype under investigation. Also different parts of plants may be inoculated to optimize observation of the expected phenotype.

- 5 Although not intending to limit the scope of the invention to a particular mode of action, it is thought that the inhibitory RNA comprised within the viral RNA vector can exercise its inhibiting effect, provided there is a balance between RNA encapsidated in a virion and free RNA. It is thought that the balance between encapsidated and free RNA may be influenced by varying the
- 10 sequence and position of an origin of assembly within the viral RNA vector. However, the gene-silencing effect may be amplified by placing the inhibitory RNA encoding nucleic acid under control of a viral promoter, preferably a coat protein promoter, or a subgenomic promoter so that during the life cycle of the virus additional inhibitory RNA is generated or transcribed.

15

- "Gene-silencing constructs" as used herein is to be interpreted as a nucleic acid, which when transcribed yield "inhibitory RNA" comprising or consisting of sense RNA or antisense RNA, or a combination of both comprising a nucleotide sequence which has at least 75%, preferably at least 80%,
- 20 particularly at least 85%, more particularly at least 90%, especially at least 95% sequence identity with or is identical to the nucleotide sequence whose expression is to be suppressed, or its complement. Further, the nucleotide sequence of the sense or antisense region should preferably be at least about 100 nucleotides in length, more preferably at least about 250 nucleotides,
- 25 particularly at least about 500 nucleotides but may extend to the full length of the coding region of the gene whose expression is to be reduced.

- For practical purposes in the application of the methods for high throughput screening or validation, the gene-silencing construct may be identical in
- 30 sequence and length to the target nucleic acids, or they may be exactly complementary in sequence and identical in length to the target nucleic acids.

WO 00/63397

PCT/EP00/03521

22

For the purpose of this invention the "sequence identity" of two related nucleotide or amino acid sequences, expressed as a percentage, refers to the number of positions in the two optimally aligned sequences which have identical residues (x100) divided by the number of positions compared. A gap, i.e. a position in an alignment where a residue is present in one sequence but not in the other is regarded as a position with non-identical residues. The alignment of the two sequences is performed by the Wilbur and Lipmann algorithm (Wilbur and Lipmann, 1983) using a window-size of 20 nucleotides or amino acids, a word length of 2 amino acids, and a gap penalty of 4. Computer-assisted analysis and interpretation of sequence data, including sequence alignment as described above, can be conveniently performed using commercially available software packages such as the programs of the Intelligenetics™ Suite (Intelligenetics Inc., CA) or the GCG Wisconsin Package.

It is clear for the person skilled in the art that the gene-silencing constructs may comprise at the same time sense and anti-sense RNA targeted towards the same nucleotide sequence whose expression is to be reduced. Preferably, the sense and antisense RNA are at least partly complementary to each other and capable of forming a stem-loop structure, since such a configuration has been shown to increase the efficiency of gene-silencing, both in occurrence and level of gene-silencing (Waterhouse et al. 1998). In the most straightforward embodiment, at least part of the target nucleic acid, preferably the complete target nucleic acid, is cloned in duplicated form, whereby the two copies are in inverted repeat, preferably separated by an unrelated spacer nucleotide sequence.

The invention also aims at providing the herein described kits in their different embodiments. It is also an object of the invention to provide the kits comprising the helper viruses and viral RNA vectors described without the gene-silencing constructs or inhibitory RNA as well as their cDNA copies, whereby the cDNA copies are under control of a promoter (which can be used in *in vitro* transcription methods available in the art) such as but not limited to



WO 00/63397

PCT/EP00/03521

23

the promoters recognized by single subunit bacteriophage polymerase promoters (T7, T3, SP6 RNA polymerase specific promoters and the like).

The invention further relates to a method for identifying genes which are essential in plants comprising the following steps:

- a) A library of random gene-silencing constructs specific for the plant is created using a viral RNA vector which is derived from a satellite RNA virus, as herein defined including all its preferred embodiments. Preferably, the library is created in a cDNA copy of the viral vector and may be generated by inserting random DNA sequences, preferably at least about 100 nucleotides in length, particularly at least about 500 nucleotides in length. The random DNA sequences may be obtained from total DNA of a plant or may represent a subset of the genome of a plant, such as DNA derived from organelles (plastids, chloroplasts, mitochondria etc.) Alternatively, the library may be created by inserting cDNAs generated by reverse transcriptase from RNA, preferably mRNA obtained from said plant. The library may be normalized, e.g. as described in Takayuki et al. (1995). The library should preferably be large enough in size, i.e. contain a sufficient number of independent clones to cover the genome of the plant, according to the standards known in the art. In a preferred embodiment, the library may contain duplication of the inserted nucleic acid whereby the copies are in inverted repeat. The inserted nucleic acid may be cloned downstream of a viral promoter such as, but not limited to a coat protein gene promoter or a subgenomic promoter. It will further be clear to the person skilled in the art that the relative orientation of the inserted nucleic acid, in relation to the RNA vector is only of limited importance since either sense or antisense inhibitory RNA will be generated.
- b) Assay plants are infected with individual members of the library and also with a corresponding helper virus. Infection may proceed according to any of the methods mentioned herein. Clearly, the DNA copy of the library should be converted into an RNA copy according to any of the methods described herein, preferably prior to the infection of the assay plants.

WO 00/63397

PCT/EP00/03521

24

- c) Plants developing a gene-silencing-construct-associated phenotype are identified. As used herein, a "gene-silencing-construct-associated phenotype" is meant to indicate a phenotype which is not observed when performing a mock inoculation with a viral RNA vector without gene-silencing construct, in combination with a corresponding helper virus on a similar plant. Preferred phenotypes comprise chlorosis, necrosis or any phenotype, preferably a morphological phenotype indicating that the infected tissue is inhibited or dying or deteriorating.
- d) Optionally, isolating the viral RNA vector from the tissue exhibiting the gene-silencing-construct-associated phenotype according to methods available in the art for isolation of virus. Preferably, the isolated viral RNA vector comprising the gene-silencing construct of interest should be re-assayed on fresh plants to confirm the observed phenotype. The viral RNA vector can of course also be recovered from the library if the infection of the plants was performed in an identity-preserving way.
- e) The gene silencing construct or the nucleotide sequence information thereof, may then be used to recover the corresponding genomic or cDNA clone using methods available in the art (hybridization, PCR etc.)
- As defined herein "essential genes" of a plant, are those genes which are necessary during the normal development of a plant. As defined, essential genes may be essential for normal development only in particular developmental stages, or only in particular tissues or organs, such as e.g. flowers. Typically, inhibition of the expression of essential genes may have a lethal effect on a plant or part of a plant. Preferred essential genes are those genes which result in retardation or dying of seedlings when inhibited.

It will be clear for the person skilled in the art that if the inhibition of the target nucleic acid results in a dominant effect, as is the case for inhibition of the expression of essential genes, the described methods may be performed using infection of more than one viral RNA vector comprising a gene-silencing construct per plant. Care has to be taken to not dilute the phenotypic effect too much by infecting a too large number of different viral RNA vectors

WO 00/63397

PCT/EP00/03521

25

comprising differing gene-silencing constructs on the same plant. It is thought that optimally any number between one and five different inhibitory RNAs may be introduced in one plant cell.

5 In yet another embodiment of the invention, a method is provided for determining the function encoded by a nucleic acid comprising a known nucleotide sequence. This nucleotide sequence may have been obtained e.g. from a genome sequencing program, including expressed sequence tags sequencing programs. In order to unravel the function of that sequence, a  
10 gene-silencing construct or inhibitory RNA targeted towards said nucleotide sequence, as described in all its embodiments herein, may be introduced into a viral RNA vector derived from a satellite virus, as described herein, and used to inoculate a plant or being introduced into a plant cell, particularly into a protoplast, together with a corresponding helper virus, as described herein.

15

A large number of the embodiments described herein thus relate to a method for the introduction of inhibitory RNA in plant cells, comprising the steps of :

- a.) introducing into a plant cell, a viral RNA vector comprising inhibitory RNA or comprising a chimeric nucleic acid which when transcribed  
20 yields the inhibitory RNA, wherein the viral RNA vector is derived from a satellite RNA virus; and
- b.) introducing into the same plant cell, a corresponding helper virus.

The methods of the invention can be applied to essentially all plants for which  
25 viral vector and/or corresponding helper viruses are available. The methods of the invention are thought to be particularly suited for Nicotina spp, particularly N. tabacum, N. sylvestris, N. benthamiana, and other Solanacea, rice (Oryza sativa) corn (Zea Mays), Brassica spp. , cotton (Gossypum hirsutum), wheat, Arabidopsis spp., Petunia spp.

30

Also envisioned by the present invention are methods for developing an agronomically useful product, such as a herbicide or a transgenic plant using the herein described methods and means, further comprising the steps of

WO 00/63397

PCT/EP00/03521

26

inserting a nucleic acid, involved in the determination of a particular plant trait, isolated by the methods of the invention, preferably under control of a foreign plant-expressible promoter, particularly under control of a controllable plant-expressible promoter into the genome of a plant, particularly a crop plant.

5 When essential genes have been identified according to the methods described herein, these essential genes or their encoded gene products, particularly the encoded proteins may be used in *in vitro* assays to identify compounds inhibiting the activity, particularly the enzymatic activity, which may be used as herbicides. Alternatively, a viral RNA vector encoding gene-

10 silencing constructs targeted towards essential genes may be used as herbicidal compounds.

The following non-limiting Examples describe the construction of viral RNA vectors derived from satellite viruses, and uses thereof. Unless stated

15 otherwise in the Examples, all recombinant DNA techniques are carried out according to standard protocols as described in Sambrook *et al.* (1989) *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, NY and in Volumes 1 and 2 of Ausubel *et al.* (1994) *Current Protocols in Molecular Biology*, *Current Protocols*, USA. Standard materials

20 and methods for plant molecular work are described in *Plant Molecular Biology Labfax* (1993) by R.D.D. Croy, jointly published by BIOS Scientific Publications Ltd (UK) and Blackwell Scientific Publications, UK.

Throughout the description and Examples, reference is made to the following

25 sequences:

SEQ ID No 1: nucleotide sequence of the genome of TNV-A

SEQ ID No 2: nucleotide sequence of the genome of TMV-U1 ( Genbank Accession Nr V01408).

30 SEQ ID No 3: nucleotide sequence of the genome of STNV-2

SEQ ID No 4: nucleotide sequence of the genome of STMV (Genbank accession Nr. M25782).

WO 00/63397

PCT/EP00/03521

27

SEQ ID No 5: nucleotide sequence of the genome of TMV-U2 ( Genbank Accession Nr M34077).

SEQ ID No 6: nucleotide sequence of the tomato phytoene desaturase (*pds*) encoding cDNA (Genbank Accession Nr. X59948).

5 SEQ ID No 7: nucleotide sequence of the tobacco nitrate reductase (*nia-2*) encoding cDNA (Genbank Accession Nr. X14059).

SEQ ID No 8: nucleotide sequence of the tobacco nitrite reductase (*nir-1*) encoding cDNA (Genbank Accession Nr. X66145).

10 SEQ ID No 9: nucleotide sequence of the  $\beta$ -1,3-glucanase( *gn-1*) encoding cDNA of *Nicotiana plumbagenifolia*.

SEQ ID No 10: nucleotide sequence of a green fluorescent protein (*gfp*) encoding region.

SEQ ID No 11: nucleotide sequence of a  $\beta$ -glucuronidase (*gus*) encoding region.

15 SEQ ID No 12: nucleotide sequence of an origin of assembly of a TMV-U2 strain.

SEQ ID No 13: nucleotide sequence of the leader sequence of a STMV strain

SEQ ID No 14: nucleotide sequence of the trailer sequence of a STMV strain.

20 SEQ ID No 15: nucleotide sequence of part of the genome of a TMV-U2 strain comprising movement protein and coat protein genes.

WO 00/63397

PCT/EP00/03521

28

## Examples

### Example I : construction of the viral RNA vector kits

5 A plasmid vector for the synthesis of an infective hybrid TMV/TNV-helper virus RNA is made using the following operationally linked elements:

- A T7 RNA polymerase promoter
- A nucleic acid comprising the nucleotide sequence from the nucleotides 1 to 2234 of TNV-A (nt 1 to 2234 of SEQ ID No 1), wherein the AUG codon  
10 at nucleotides 2218-2220 mutated to a different codon
- A nucleic acid comprising the nucleotide sequence encoding the open reading frame for the movement protein of TMV-U1 (nt 4903-5709 of Genbank Accession Number V01408 or nt 4903-5709 of SEQ ID No 2 or nt 479-1285 of SEQ ID No 12)
- 15 • A nucleic acid comprising the nucleotide sequence from the nucleotides 2235 to 2612 of TNV-A (SEQ ID No 1)
- A nucleic acid comprising the nucleotide sequence encoding the open reading frame for the coat protein of TMV-U1 (nt 5712-6191 of Genbank Accession Number V01408 or nt 5712-6191 of SEQ ID No 2 or nt 1288-  
20 1767 of SEQ ID No 15)
- A sequence comprising nucleotide 3444 to 3684 of TNV-A (nt 3444 to 3684 of SEQ ID No 1)

25 A plasmid vector for the synthesis of an infective hybrid TMV/STNV viral vector RNA is made using the following operationally linked elements:

- A T7 RNA polymerase promoter
- A nucleic acid comprising the nucleotide sequence from nucleotide 1 to 32 of STNV-2 (nt 1 to 32 of SEQ ID No 3)
- A nucleic acid comprising the origin of assembly (OAS) of TMV-U1 (nt.  
30 5443-5518 of Genbank Accession Number V01408 or nt 5443-5518 of SEQ ID No 2 or nt 1018 to 1094 of SEQ ID No 15)
- A nucleic acid comprising the nucleotide sequence from nucleotide 738 to 1245 of STNV-2 (nt 738 to 1245 of SEQ ID No 3)

WO 00/63397

PCT/EP00/03521

29

A plasmid vector for the synthesis of an infective hybrid TMV/STMV viral vector RNA is made using the following operationally linked elements:

- A T7 RNA polymerase promoter
- 5 • A nucleic acid comprising the nucleotide sequence from nucleotide 1 to 197 of STMV (Genbank Accession Number M25782; nt 1 to 197 of SEQ ID No 4) or the nucleotide sequence of SEQ ID No 13.
- A nucleic acid comprising the OAS of TMV-U1 (nt. 5443-5518 of Genbank Accession Number V01408; nt 5443 to 5518 of SEQ ID No 2; nt 1019-1094 of SEQ ID No 15) or of TMV-U2 (nt 5430-5505 of Genbank Accession Number M34077; nt 5430-5505 of SEQ ID No 5) such as the
- 10 nucleotide sequence of SEQ ID No 12.
- A nucleic acid comprising the nucleotide sequence from nucleotide 604 to 1058 of STMV (Genbank Accession Number M25782; nt 604 to 1058 of
- 15 SEQ ID No 4) or comprising the nucleotide sequence of SEQ ID No 14.

**Example 2. Feasibility demonstration using known endogenes or transgenes.**

20 To demonstrate the feasibility of the use of the viral kits described sub example 1 for functional knockout of specific endo- or transgenes in *Nicotiana* plants, one of the following DNA fragments is inserted in the TMV/STNV or TMV/STMV hybrid vector, immediately upstream or downstream of the TMV OAS:

- 25 • a fragment of the tomato pythoene desaturase (*pds*) cDNA (comprising nucleotide 1021 to 1671 of SEQ ID No 6 or Genbank Accession Number X59948)
- a fragment of the tobacco nitrate reductase (*nia-2*) cDNA (comprising nucleotides 1103 to 2114 or nucleotides 5169 to 6497 of SEQ ID No 7 or
- 30 Genbank Accession Number X14059)
- a fragment of the tobacco nitrite reductase (*nir-1*) cDNA (comprising nucleotide 650-1212 of SEQ ID No 8 or Genbank Accession Number X66145)

WO 00/63397

PCT/EP00/03521

30

- a fragment of the  $\beta$ -1,3-glucanase (*gn-1*) cDNA of *Nicotiana plumbaginifolia* (SEQ ID No 9 or Genbank Accession Number X07280)
- a fragment comprising a nucleotide sequence from a green fluorescent protein (*gfp*) coding region (SEQ ID No 10)
- 5 • a fragment comprising a nucleotide sequence from nucleotide 1 to 600 of the  $\beta$ -glucuronidase (*gus*) coding region (SEQ ID No 11)

Infective chimeric transcripts are synthesized *in vitro*, using T7 RNA polymerase with the linearized plasmid DNAs of the described vectors as  
10 templates.

The TMV/STNV RNAs are mechanically inoculated on leaves of *Nicotiana benthamiana* or *Nicotiana tabacum* plants together with the TMV/TNV RNA, whereas the TMV/STMV RNAs are inoculated together with TMV-U2 virus particles or viral RNA.

15 The infected plants are scored for phenotypes, virus accumulation, and suppression of the homologous plant gene between 1 and 4 weeks after inoculation.

Plants infected with vectors containing the *pds* cDNA show a bleaching phenotype on infected leaves and silencing of the endogenous *pds* transcript.

20 Plants infected with vectors containing the *nia-2* or *nir-1* cDNA show a chlorotic phenotype on infected leaves and silencing of the endogenous *nia-2* or *nir-1* transcript, respectively.

Plants infected with vectors containing the *gn-1* cDNA show silencing of the endogenous basic -1,3-glucanase transcript.

25 Upon infection with vectors containing the *gfp* sequence, transgenic plants that normally express a *gfp* transgene show silencing of the *gfp* transgene transcript and suppression of GFP fluorescence.

Upon infection with vectors containing the *gus* sequence, transgenic plants that normally express a *gus* transgene show silencing of the *gus* transgene  
30 transcript and suppression of GUS activity.



WO 00/63397

PCT/EP00/03521

31

**Example 3: Inactivation of phytoene desaturase in *Nicotiana benthamiana* using a TNV/STNV hybrid vector system.**

A TNV/STNV hybrid vector system was used for the functional inactivation of a constitutively expressed endogenous plant gene. Therefore, the following STNV hybrid vectors have been constructed:

pIF9 carrying the following operationally linked elements:

- a T7 RNA polymerase promoter comprising nucleotide 402 to 420 of Genbank Accession Number M77811;
- a nucleic acid comprising the nucleotide sequence from nucleotide 1 to 32 of SEQ ID No 3 (STNV-2 leader);
- a nucleic acid comprising the origin of assembly (OAS) of TMV-U1 from nucleotide 5443 to 5518 of SEQ ID No 2 or Genbank Accession Number V01408;
- a fragment of the tomato phytoene desaturase (pds) cDNA comprising nucleotide 1021 to 1671 of SEQ ID No 6 or Genbank Accession Number X59948;
- a nucleic acid comprising the nucleotide sequence from nucleotide 806 to 1418 of SEQ ID No 3 (STNV-2 trailer).

pIF12 carrying the following operationally linked elements:

- a T7 RNA polymerase promoter comprising nucleotide 402 to 420 of Genbank Accession Number M77811;
- a nucleic acid comprising the nucleotide sequence from nucleotide 1 to 32 of SEQ ID No 3 (STNV-2 leader);
- a fragment of the tomato phytoene desaturase (pds) cDNA comprising nucleotide 1021 to 1671 of SEQ ID No 6 or Genbank Accession Number X59948;
- a nucleic acid comprising the nucleotide sequence from nucleotide 742 to 1354 of SEQ ID No 3 (STNV-2 trailer).

WO 00/63397

PCT/EP00/03521

32

Infective chimeric transcripts have been synthesized in vitro using T7 RNA polymerase with the linearized plasmid DNAs of the described pIF9 and pIF12 hybrid vectors as templates using standard procedures. Control in vitro transcripts have been synthesized on linearized plasmid DNAs of the precursor plasmids of pIF9 and pIF12 without the pds fragment inserts and on linearized plasmid DNA of an infective clone of the STNV wild type and of a hybrid STNV vector carrying an insert of the cat gene.

The in-vitro transcripts have been mechanically inoculated onto leaves of four weeks old *Nicotiana benthamiana* plants together with the TNV helper virus.

All infected plants were continuously scored for pds inactivation, which resulted in a phenotype showing leaf bleaching. For all inoculations necrotic lesions were observed for the inoculated leaves after 2 days post inoculation (p.i.). Within a week, necrotic lesions also occurred in upper leaves indicating the systemic spread of the viruses in *N.benthamiana*. In most infected plants, the virus symptoms have been severe but plants survived for many weeks.

Only plants, which have been infected with the hybrid vectors pIF9 and pIF12 carrying pds fragments, showed on top of the virus symptoms additional phenotypic changes. Approximately 4 weeks p.i., green upper leaves, which did not show any virus symptoms, developed bleached spots scattered all over the leaves. The bleaching was progressive and was not accompanied by necrotic lesions. Within another three weeks, the size of the spots increased constantly and the color changed from pale green to yellow to pale white-yellow. These symptoms have never been observed in plants, on which TNV/STNV wild type or TNV/STNV-deletion mutant control inoculations were carried out. Thus, this phenotype indicates the functional knockout of pds in *N. benthamiana* plants after infection with pIF9 and pIF12 hybrid viral vectors.

30

In RNA gel blot analyses performed with total RNA preparations of green and bleached spots of upper leaves of plants showing a FKO phenotype no chimeric STNV virus RNA and only very low levels of TNV helper virus RNA

WO 00/63397

PCT/EP00/03521

33

could be detected. This indicates that virus induced gene silencing of pds in a specific tissue does not need to be accompanied by high levels of virus RNA.

**Example 4: Inactivation of phytoene desaturase in *Petunia hybrida* using a TMV/STMV hybrid vector system.**

A TMV/STMV hybrid vector system was used for the functional inactivation of a constitutively expressed endogenous plant gene. Therefore, the following STMV hybrid vectors have been constructed:

10

pVE293 carrying the following operationally linked elements:

- a T7 RNA polymerase promoter comprising nucleotide 402 to 420 of Genbank Accession Number M77811
- a nucleic acid comprising the nucleotide sequence from nucleotide 1 to 197 of STMV of SEQ ID No 4 or Genbank Accession Number M25782 (STMV leader)
- a nucleic acid comprising the origin of assembly (OAS) of TMV-U2 from nucleotide 5430 to 5505 of SEQ ID No 5 or Genbank Accession Number M34077 ("short" TMV OAS)
- a fragment of the tomato phytoene desaturase (pds) cDNA comprising nucleotide 1021 to 1671 of SEQ ID No 6 or Genbank Accession Number X59948
- a nucleic acid comprising the nucleotide sequence from nucleotide 604 to 1058 of STMV of SEQ ID No 4 or Genbank Accession Number M25782 (STMV trailer)
- a SP6 RNA polymerase promoter comprising nucleotide 143 to 124 of Genbank Accession Number X65308

25

pVE294 carrying the following operationally linked elements:

30

- a T7 RNA polymerase promoter comprising nucleotide 402 to 420 of Genbank Accession Number M77811

WO 00/63397

PCT/EP00/03521

34

- a nucleic acid comprising the nucleotide sequence from nucleotide 1 to 197 of STMV of SEQ ID No 4 or Genbank Accession Number M25782 (STMV leader)
- a nucleic acid comprising the origin of assembly (OAS) of TMV-U2 from nucleotide 5441 to 5849 of SEQ ID No 2 or Genbank Accession Number M34077 ("long" TMV OAS)
- a fragment of the tomato phytoene desaturase (pds) cDNA comprising nucleotide 1021 to 1671 of SEQ ID No 6 or Genbank Accession Number X59948
- a nucleic acid comprising the nucleotide sequence from nucleotide 604 to 1058 of STMV of SEQ ID No 4 or Genbank Accession Number M25782 (STMV trailer)
- a SP6 RNA polymerase promoter comprising nucleotide 143 to 124 of Genbank Accession Number X65308

Infective chimeric transcripts have been synthesized in vitro using T7 RNA polymerase with the linearized plasmid DNAs of the described pVE293 and pVE294 hybrid vectors as templates using standard procedures. Control in vitro transcripts have been synthesized on linearized plasmid DNAs of the precursor plasmids of pVE293 and pVE294 without the pds fragment insert and on linearized plasmid DNA of the infective clone STMV-10 of the wild type.

The in vitro transcripts have been mechanically inoculated onto leaves of three months old *Petunia hybrida* V26 plants together with the TMV-U2 helper virus.

The infected plants have been continuously scored for pds inactivation, which resulted in a phenotype showing leaf bleaching. The infection of petunia plants with TMV/STMV caused the occurrence of crinkled leaves starting from the infected branches but quickly progressing systemically throughout the plant. The plants did survive the infections and often showed recovery phenotypes with almost no symptoms.

WO 00/63397

PCT/EP00/03521

35

Only the plants, which have been infected with the hybrid vectors pVE293 and pVE294 carrying the pds fragment, showed in addition to the virus symptoms, additional phenotypic changes. In case of TMV/pVE293 infections, the infected branches developed young leaves with bleached sectors around the veins and at the tip of the leaves. This bleaching was progressive and independent from the presence of virus symptoms. Some of the leaves were fully bleached and progressively changed into almost white color. This phenotype was restricted to leaves of the infected branches. In case of TMV/pVE294 infections a similar bleaching of young leaves was observed for all developing branches but not for branches carrying already terminal flower buds. The bleaching started again around the veins and leaf tips but proceeded quickly producing variable leaf variegation patterns. This phenotype has never been observed in control inoculations with wild type viruses or deletion mutants. Therefore this phenotype indicates the functional knockout of pds in *Petunia hybrida* plants after infection with pVE293 and pVE294 viral hybrid vectors.

In RNA gel blot analyses performed with total RNA preparations of green and bleached spots of upper leaves of plants showing a FKO phenotype no chimeric STMV virus RNA and only low levels of TMV helper-virus RNA could be detected. This indicates that virus induced gene silencing of pds in a specific tissue does not need to be accompanied by high levels of virus RNA.

WO 00/63397

PCT/EP00/03521

36

## REFERENCES

- Ausubel *et al.* (1994) *Current Protocols in Molecular Biology*, Current Protocols, USA.
- Baulcombe (1996) *Plant Cell* 8: 1833-1844
- 5 Baulcombe *et al.* (1998) *JIC & SL Annual Report 1996/1997*
- Bringle *et al.* (1998) 79: 1539-1546
- Chapman (1991) PhD dissertation, University of Cambridge, UK
- Coutts *et al.* (1991) *J. Gen. Virology* 72: 1521-1529
- Danthinne *et al.* (1991) *Virology* 185: 605-614
- 10 Depicker and Van Montagu (1997) *Curr. Opin. Cell. Biol.* 9: 373-382
- English *et al.* (1996) *Plant Cell* 8, 179-188
- Hamilton *et al.* (1998) *The Plant Journal* 15(6): 737-746
- Kempin *et al.* (1997) *Nature* 389: 802-803
- Kumagai *et al.* (1995) *Proc. Natl. Acad. Sci USA* 92: 1679-1683
- 15 Meulewaeter *et al.* (1990) *Virology* 177:699-709
- Pereira and Aerts (1998) *Methods in Molecular Biology* 82 Eds. Martinez-Zapatar and Salinas, Humana Press, NJ
- R.D.D. Croy (1993) *Plant Molecular Biology Labfax* jointly published by BIOS Scientific Publications Ltd (UK) and Blackwell Scientific
- 20 Publications, UK.
- Prahasar *et al.* (1996) *Proc. Natl. Acad. Sci USA* 93: 659-663
- Ruiz *et al.* (1998) *The Plant Cell* 10: 937-946
- Sambrook *et al.* (1989) *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, NY
- 25 Stam *et al.* (1997) *Ann. Botan.* 79:3-12
- Takayuki *et al.* (1995) *The Plant Journal* 8(5):771-776
- Walkey (1985) *Applied Virology*, William Heinemann Ltd, London
- Waterhouse *et al.* (1998) *Proc. Natl. Acad. Sci USA* 95: 13959-13964
- Wellink *et al.* (1998) Abstract presented at the Joint Meeting of Arbeitskreis
- 30 Virologie and Nederlandse Kring voor Plantenvirologie in Wageningen, The Netherlands, November 12 and 13, 1998.
- Wilbur and Lipmann (1983) *Proc. Nat. Acad. Sci. USA* 80: 726
- Ysebaert *et al.* (1980) *J. Mol. Biol.* 143: 273-287

WO 00/63397

PCT/EP00/03521

37

## Claims

1. A method for isolating genes involved in the determination of a trait or phenotype of a plant species, said method comprising
  - 5 a.) Identifying a set of nucleic acid sequences of genes, whose expression is correlated with a trait of interest.
  - b.) creating a library of gene silencing constructs in a viral RNA vector, said viral RNA vector being capable of replication inside plant cells and optionally movement between plant cells of a plant, and said gene
    - 10 silencing constructs being targeted to the nucleotide sequence of said nucleic acid sequences;
    - c.) infecting a collection of individual plants of said plant species with said library of gene silencing constructs, whereby each plant is infected with at least one member of said library;
    - 15 d.) identifying a plant wherein said trait or phenotype is altered, using an assay adapted to said trait or phenotype;
    - e.) isolating said gene involved in the determination of said trait or phenotype in said plant species, from said library based on the nucleotide sequence to which said gene silencing construct in said
      - 20 identified plant was targeted.
2. The method of claim 1, wherein said viral RNA vector is capable of autonomous replication inside plant cells and optionally autonomous movement between plant cells.
- 25 3. The method of claim 2, wherein said viral RNA vector is derived from cowpea mosaic virus.
4. The method of claim 1, wherein said viral RNA vector is capable of
  - 30 replication inside plant cells and optionally movement between plant cells when the required factors are supplemented *in trans*.

WO 00/63397

PCT/EP00/03521

38

5. The method of claim 4, wherein said viral RNA vector is derived from a satellite RNA virus and said factors are supplemented by infection with a helper virus or helper virus RNA.
- 5 6. The method of claim 5, wherein said satellite RNA virus is satellite tobacco mosaic virus.
7. The method of claim 6, wherein said viral RNA vector comprises an origin of assembly of tobacco mosaic virus.
- 10 8. The method of claim 7, wherein said helper virus is tobacco mosaic virus.
9. The method of claim 5, wherein said satellite RNA virus is satellite tobacco necrosis virus.
- 15 10. The method of claim 9, wherein said viral RNA vector comprises an origin of assembly of tobacco mosaic virus.
11. The method of claim 10, wherein said helper virus is derived from tobacco necrosis virus and comprises a coat protein gene of tobacco mosaic virus and optionally a movement protein gene of tobacco mosaic virus.
- 20 12. The method of claim 11, wherein said satellite RNA virus is satellite tobacco necrosis vector strain 1 or 2 and said helper virus is derived from TNV-A.
- 25 13. The method of claim 11, wherein said satellite RNA virus is STNV-C and said helper virus is derived from TNV-D.
- 30 14. The method of claim 1, wherein said gene-silencing constructs comprise antisense RNA.



WO 00/63397

PCT/EP00/03521

39

15. The method of claim 1, wherein said gene-silencing constructs comprise sense RNA.
16. The method of claim 1, wherein said gene-silencing constructs comprise  
5 an inverted repeat.
17. The method of claim 1, wherein said gene-silencing constructs comprise complementary stretch of at least 50 nucleotides of sense and antisense RNA.  
10
18. The method of claim 17, wherein said gene-silencing constructs comprise complementary stretch of at least 100 nucleotides of sense and antisense RNA.
- 15 19. The method of claim 17, wherein said gene-silencing constructs comprise at least two copies of part of the nucleotide sequences of said collection of nucleic acids, said copies being in inverted repeat.
20. A method for the isolation of a nucleic acid with a specific function from a  
20 collection of nucleic acids, said collection of nucleic acids being characterized in that variation in the expression pattern of said nucleic acids is correlated with variation in a trait/phenotype of a plant harboring said nucleic acids, said method comprising the steps of
- 25 a.) creating a library of gene silencing constructs in a viral RNA vector, said viral RNA vector being capable of replication inside and optionally movement between plant cells, and said gene silencing constructs being targeted/adapted to the nucleotide sequence of said nucleic acids;
- 30 b.) infecting a collection of plants with said library of gene silencing constructs, whereby each plant is infected with at least one member of said library;
- c.) identifying plants with altered trait or phenotype using an assay adapted to said trait or phenotype.

WO 00/63397

PCT/EP00/03521

40

- 5 21. The method of claim 20, further comprising the step of isolating said nucleic acid with said specific function from said identified plant with altered trait or phenotype.
22. A method for determining the function encoded by a nucleic acid  
10 comprising a known nucleotide sequence in a plant, said method comprising
- a.) providing a viral RNA vector, said viral RNA vector being derived from a satellite RNA virus, comprising a gene-silencing construct targeted to a gene comprising said known nucleotide sequence;
- 15 b.) infecting said plant with said viral RNA vector and a corresponding helper virus;
- c.) identifying an altered trait or phenotype of said co-infected plant.
23. A method for isolating essential genes in a plant, comprising
- 20 a.) creating a library of random gene-silencing constructs for said plant comprised within a viral RNA vector, said viral RNA vector being derived from a satellite RNA virus;
- b.) infecting a plant with at least one member of said library and with a corresponding helper virus;
- 25 c.) identifying plants developing a gene-silencing-construct-associated phenotype, preferably chlorosis or necrosis.
24. The method according to claim 23, further comprising the step of isolating the viral RNA vector from the tissue exhibiting the phenotype.
- 30 25. The method of claim 23, wherein said library is created by cloning random DNA fragments of said plant in a cDNA copy of the viral RNA vector.

WO 00/63397

PCT/EP00/03521

41

26. The method of claim 23, wherein said library is created by cloning random cDNA fragments of said plant in a cDNA copy of the viral RNA vector.

27. The method of claim 23, wherein said library is created by cloning random duplicated cDNA fragments in inverted repeat.

28. The method of claim 23, wherein said viral RNA vector is derived from STMV and comprises an origin of assembly of tobacco mosaic virus, and wherein said helper virus is tobacco mosaic virus.

10

29. The method of claim 23, wherein said viral RNA vector is derived from satellite tobacco necrosis virus and comprises an origin of assembly of tobacco mosaic virus and wherein said helper virus is derived from tobacco necrosis virus and comprises a coat protein gene of tobacco mosaic virus and optionally a movement protein gene of tobacco mosaic virus.

15

30. The method of claim 29, wherein said satellite RNA virus is satellite tobacco necrosis vector strain 1 or 2 and said helper virus is derived from TNV-A.

20

31. The method of claim 29, wherein said satellite RNA virus is STNV-C and said helper virus is derived from TNV-D.

32. A method for the introduction of inhibitory RNA in the cytoplasm of plant cells, said method comprising:

a.) introducing into said plant cell, a viral RNA vector comprising said inhibitory RNA or comprising a chimeric nucleic acid which when transcribed yields said inhibitory RNA, wherein said viral RNA vector is derived from a satellite RNA virus; and

b.) introducing a corresponding helper virus into said plant cell.

30

WO 00/63397

PCT/EP00/03521

42

33. The method of claim 32, wherein said inhibitory RNA comprises sense RNA.
34. The method of claim 32, wherein said inhibitory RNA comprises antisense RNA.
35. The method of claim 32, wherein said inhibitory RNA comprises an inverted repeat.
36. The method of claim 32, wherein said inhibitory RNA comprises complementary stretch of at least 50 nucleotides of sense and antisense RNA.
37. The method of claim 36, wherein said inhibitory RNA comprises complementary stretch of at least 100 nucleotides of sense and antisense RNA.
38. The method of claim 32, wherein said viral RNA vector is derived from STMV and comprises an origin of assembly of tobacco mosaic virus, and wherein said helper virus is tobacco mosaic virus.
39. The method of claim 32, wherein said viral RNA vector is derived from satellite tobacco necrosis virus and comprises an origin of assembly of tobacco mosaic virus and wherein said helper virus is derived from tobacco necrosis virus and comprises a coat protein gene of tobacco mosaic virus and optionally a movement protein gene of tobacco mosaic virus.
40. The method of claim 39, wherein said satellite RNA virus is satellite tobacco necrosis vector strain 1 or 2 and said helper virus is derived from TNV-A.

WO 00/63397

PCT/EP00/03521

43

41. The method of claim 39, wherein said satellite RNA virus is STNV-C and said helper virus is derived from TNV-D.
42. The method of any one of claims 32 to 41, wherein said plant is selected from Nicotina spp, Oryza sativa, Zea Mays, Brassica spp. , Gossypum spp., Triticum spp., Arabidopsis spp. or Petunia spp.
43. A kit for introduction of inhibitory RNA in the cytoplasm of a plant cell, said kit comprising
  - a.) a viral RNA vector derived from a satellite RNA virus, said vector comprising a chimeric nucleic acid which when transcribed yields said inhibitory RNA or which comprises said inhibitory RNA; and
  - b.) a corresponding helper virus.
44. The kit of claim 43, wherein said inhibitory RNA comprises sense RNA.
45. The kit of claim 43, wherein said inhibitory RNA comprises antisense RNA.
46. The kit of claim 43, wherein said inhibitory RNA comprises an inverted repeat.
47. The kit of claim 43, wherein said inhibitory RNA comprises complementary stretch of at least 50 nucleotides of sense and antisense RNA.
48. The kit of claim 43, wherein said inhibitory RNA comprises complementary stretch of at least 100 nucleotides of sense and antisense RNA.
49. The kit of claim 43, wherein said viral RNA vector is derived from STMV and comprises an origin of assembly of tobacco mosaic virus, and wherein said corresponding helper virus is tobacco mosaic virus.

WO 00/63397

PCT/EP00/03521

44

50. The kit of claim 43, wherein said viral RNA vector is derived from satellite tobacco necrosis virus and comprises an origin of assembly of tobacco mosaic virus and wherein said corresponding helper virus is derived from tobacco necrosis virus and comprises the coat protein gene of tobacco mosaic virus and optionally the movement protein gene of tobacco mosaic virus.
51. The kit of claim 50, wherein said satellite RNA virus is satellite tobacco necrosis vector strain 1 or 2 and said corresponding helper virus is derived from TNV-A.
52. The kit of claim 50, wherein said satellite RNA virus is STNV-C and said corresponding helper virus is derived from TNV-D.


10/526475

PCT/EP00/03521


WO 00/63397

1/1

1. Tobacco mosaic virus



2. Tobacco necrosis virus



3. Satellite tobacco mosaic virus



4. Satellite tobacco necrosis virus



10/526475  
BT01 Rec'd PCT/PT 03 MAR 2005  
PCT/EP00/03521

WO 00/63397

## SEQUENCE LISTING

&lt;110&gt; Aventis CropScience N.V.

<120> Methods and means for delivering inhibitory RNA to  
plants and applications thereof

&lt;130&gt; FKOSAT

&lt;140&gt;

&lt;141&gt;

&lt;150&gt; US SN 09/294022

&lt;151&gt; 1999-04-20

&lt;160&gt; 15

&lt;170&gt; PatentIn Ver. 2.1

&lt;210&gt; 1

&lt;211&gt; 3684

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:cDNA copy of  
the nucleotide sequence of the genome of TNV-A

&lt;400&gt; 1

agtattcata ccaagaatac caaataggtg caaggcctta ctcagctaaa gagtctaaaa 60  
tggagctacc aaaccaacac aagcaaacgg ccgccgaggg ttctgtatct ttctaaact 120  
ggctatgcaa cccatggaga cgacagcgaa cagtcaacgc tgcagttgcg ttccaaaaag 180  
atcttctcgc cattgaggat tccgagcatt tggatgacat caatgagtgt ttcgaggagt 240  
ctgctggggc acaatctcag cgaactaagg ttgtcgccga cggagcatat gcccccgcaa 300  
aatccaacag gacccgccga gttcgtaagc agaagaagca caagtttgta aaatatcttg 360  
tcaacgaagc tcgtgccgag tttggattgc ccaaaccaac tgaggcaaac agacttatgg 420  
tccaacattt cttgctcaga gtgtgcaagg attggggcgt tgttactgcc cacgtacacg 480  
gcaatgttgc actagctttg ccaactggtgt tcatcccaac ggaagatgat ctgctatcac 540  
gagcattgat gaacacacat gctactagag ccgctgtacg aggcattggac aatgtccaag 600  
gggaggggtg gtggaacaat aggttgggga ttggggggcca ggtcggactg gccttccggt 660  
ccaaataggg gtgccttgaa aggaggccag gattctccac gtccgtttcg .cgtggggaac 720  
atcctgatct ggtggtcata ccatcagggc gccctgagaa acagcgtcag ttgttacgct 780  
atagtggtat aggcggccat ttattaatcg gcatccacaa caactctctt tccaacctgc 840  
gtaggggctt gatggaaaga gtattctatg tcgagggggc caatgggctt caagacgccc 900  
ctaagcccg tcaagggagct ttctgaaccc ttgataagtt tcgtgatctc tatactaaaa 960  
atagttggcg tcatacccct gtaactagtg aacaattcct aatgaattac acgggcagga 1020  
aactgactat ttacagagag gcggttgata gtttgtcgca tcaaccctt agctcacgag 1080  
atgcgaaact aaagacattc gtgaaggccg aaaaattaaa tcttttctaag aagcctgacc 1140



WO 00/63397

PCT/EP00/03521

```

ctgctcccag ggtcatccaa cctagatcgc ctcggtataa cgtttgtttg ggcaggtacc 1200
tccgacatta tgagcatcac gcgtttaaaa ccattgccaa gtgctttggg gaaatcacgg 1260
tcttcaaagg gtttactctg gagcaacaag gggaaatcat gcgctcgaag tggaataaat 1320
atgttaatcc cgtcgcagtc ggactcgacg ccagtcgttt cgaccaacac gtgtctgttg 1380
aagcactcga gtatgagcat gaattttacc tcagagacta cccaaatgat aaacagctaa 1440
aatggctgct aaagcagcaa ttgtgcaacg taggaacggc attcgccagt gacggcatta 1500
taaaatacaa gaagaagggt tgtagaatga gcggagacat gaacacgagt ttgggcaact 1560
gcattctaag gtgcgccatg gtctacgggt tgaaagaaca cttaaacatc aatttgccc 1620
ttgcaaataa tggggatgac tgcgtcattg tctgtgagaa agcggattta aagaaattga 1680
caagcagcat cgagccatat ttcaagcagt ttggattcaa gatggaagtg gaaaaacccg 1740
tggatatatt tgagcgcata gaattttgcc aaaccaacc tgtgttcgat ggatcccagt 1800
acatcatggt acgcaaacct tctgtggtta catctaaaga cgtcactagc cttatcccat 1860
gtcaaacgaa agcacaatac gcagaatggc tgcaagctgt aggtgagtgt ggcagtgagca 1920
ttaacgggtg gattcctgtc atgcagaatt tctacaaaa gctccaaact ggcacccg 1980
gcacaaaatt caccaagacc ggcgagttcc agacgaacgg attgggggat cactctagat 2040
atatgcatag agtggcccg gttccttcgc ctgaaacccg tttatccttc tatctagctt 2100
tcggtatcac accagacctc caagaagcat tggagatctt ctatgatacc cacaggcttg 2160
agttggatga tgttatccca actgatacct accaagtgtc aggagagcat ttgatcaatg 2220
gattacaaaa ctgatgtaac ggaggacaat gtgcaaatat gcggtcgggc taggagcgtt 2280
gagggttaaga aacacaatgg ttcgggatta actggcggtta agcgtcacgc ggtgagcgaa 2340
acatctcaga aatcacagca aggtactggc aatggaacta tgaccaatat agccgaagaa 2400
cagaccatta ccgtgacata caactttaac ttttaagtta tggctgcgtg tcgctgttgt 2460
gatacttcac cagggtattac actattccct tactttgcaa ttctatcct tatattggca 2520
atacttggtg tagggactcc caatcaaaa tatcaccatt ctccaagcac ttacgagtac 2580
aagactcaac acatttcgat cgcaaaatag acatggcagg aaagaagaac aacaacaacg 2640
gtcagtatat aatactgcgt actccagagc aacagggtgga gatagaccag cgcaacgccc 2700
gtcgtgctca aatgggtcgc atgaagaagg ctagacagcc cgttcagcga tacttacagc 2760
aacacgggtt gcgaaacgga ttgtccggtg gagggggcta catagtggct cccacctccg 2820
ggggggttgt cactcgacct atagtgccga aattctccaa caggggagat tccactatag 2880
tccgtaaacac tgagattttg aacaaccaa tcttagcggc gctaggcgca ttcaatacaa 2940
caaactccgc actgattgca gcagcaccat catggctggc tagcatcgct gatctttaca 3000
gtaaatagag atggctctca tgtgagatca tctacattcc aaaatgcccc accaccacca 3060
gtggatcaat tgccatggct ttcacatacg acagaaatga cgctgcaccc accgcaaggg 3120
ctcagctgtc acaatcttac aaggccatca attttccacc gtatgcggga tacgacggag 3180
cagcatattt gaattcgaac caggagctg ggtcagccat cgccgttcaa cttgatgtta 3240
ccaagtggga caagccatgg taccacctta tctcctctgc cggttcggg gcgctcagcg 3300
tctcgtatca gaaccaatc tgccccgct cccttggtgt cgctagcgat gggggacccg 3360
ctactgtac tccagcaggg gaccttttca tcaagtacgt gattgagttc attgaacca 3420
tcaacccaac aatgaacgct tagttctttg tactgtaact tggctaattg ctaagggtgga 3480
gtcacaccat tggagacgga gacggatcct gggaaacagg cttgacgggc ggggggtggt 3540
gccccgacg acgcatcact ccggatacca atggtacacc actatggcag ggtctgcaa 3600
ggtcttggtc accaagaacc cctggaaacg ggggggaggg gggtagcaca tatcatccag 3660
attgaggggc ctttgcacca cccc 3684

```

<210> 2

<211> 6395

<212> DNA

<213> Artificial Sequence

WO 00/63397

PCT/EP00/03521

&lt;220&gt;

<223> Description of Artificial Sequence: cDNA copy of  
the nucleotide sequence of the genome of TMV-U1

&lt;400&gt; 2

```

gtatttttac aacaattacc aacaacaaca aacaacaaac aacattacaa ttactattta 60
caattacaat ggcatacaca cagacagcta ccacatcagc tttgctggac actgtccgag 120
gaaacaactc cttgggtcaat gatctagcaa agcgtcgtct ttacgacaca gcgggttgaa 180
agttaaacgc tcgtgaccgc agggcccaagg tgaacttttc aaaagtaata agcgaggagc 240
agacgcttat tgctaccgag gcgtatccag aattccaaat tacattttat aacacgcaaa 300
atgccgtgca ttcgcttgca ggtggattgc gatctttaga actggaatat ctgatgatgc 360
aaattcccta cggatcattg acttatgaca taggcgggaa ttttgcacgc catctgttca 420
agggacgagc atatgtacac tgctgcatgc ccaacctgga cgttcgagac atcatgcggc 480
acgaaggcca gaaagacagt attgaactat acctttctag gctagagaga ggggggaaaa 540
cagtcccaaa cttccaaaag gaagcatttg acagatacgc agaaattcct gaagacgctg 600
tctgtcacia tactttccag acaatgcgac atcagccgat gcagcaatca ggcagagtgt 660
atgccattgc gctacacagc atatatgaca taccagccga tgagtccggg gcggcactct 720
tgaggaaaaa tgtccatacg tgctatgccg ctttccactt ctctgagaac ctgcttcttg 780
aagattcata cgtcaatttg gacgaaatca acgcgtgttt ttccgcgat ggagacaagt 840
tgaccttttc ttttgcacga gagagtactc ttaattattg tcatagtatt tctaattatt 900
ttaagtatgt gtgcaaaact tacttcccg cctctaatag agagggtttac atgaaggagt 960
ttttagtcac cagagttaat acctgggttt gtaagttttc tagaatagat acttttcttt 1020
tgtacaaagg tgtggcccat aaaagtgtag atagttagca gttttatact gcaatggaag 1080
acgcatggca ttacaaaaag actcttgcaa tgtgcaacag cgagagaatc ctcttgagg 1140
attcatcatc agtcaattac tgggttccca aaatgaggga tatggtcac gtaccattat 1200
tcgacatttc tttggagact agtaagagga cgcgcaagga agtcttagtg tccaaggatt 1260
tcgtgtttac agtgcttaac cacattcgaa cataccaggc gaaagctctt acatacgcaa 1320
atgttttgtc ctttgtcgaa tcgattcgat cgagggtaat cattaacggt gtgacagcga 1380
gggccgaatg ggatgtggac aaatctttgt tacaatcctt gtccatgacg ttttacctgc 1440
atactaagct tgccgttcta aaggatgact tactgattag caagtttagt ctcggttcga 1500
aaacgggtgt ccagcatgtg tgggatgaga tttcgtggc gtttgggaac gcatttccct 1560
ccgtgaaaga gaggctcttg aacaggaaac ttatcagagt ggcaggcgac gcattagaga 1620
tcagggtgcc tgatctatat gtgaccttcc acgacagatt agtgactgag tacaaggcct 1680
ctgtggacat gcctgcgctt gacattagga agaagatgga agaaacggaa gtgatgtaca 1740
atgcactttc agagtatatg gtgttaaggg agtctgacaa attcgatgtt gatgtttttt 1800
cccagatgtg ccaatctttg gaagttgacc caatgacggc agcgaagggt atagtcgcgg 1860
tcatgagcaa tgagagcggc ctgactctca catttgaaac acctactgag gcgaatgttg 1920
cgctagcttt acaggatcaa gagaaggctt cagaagggtg tttggtagtt acctcaagag 1980
aagttgaaga accgtccatg aagggttcga tggccagagg agagttacaa ttagctggtc 2040
ttgttgagga tcatccggag tcgtcctatt ctaagaacga ggagatagag tcttttagagc 2100
agtttcatat ggcaacggca gattcgttaa ttcgtaagca gatgagctcg attgtgtaca 2160
cgggtccgat taaagttcag caaatgaaaa accttatcga tagcctggta gcatactat 2220
ctgtgcgggt gtcgaatctc gtcaagatcc tcaaagatac agctgctatt gaccttgaaa 2280
cccgtcaaaa gtttggagtc ttggatgttg catctaggaa gtggttaate aaaccaacgg 2340
ccaagagtca tgcattgggt gttgttgaaa cccacgcgag gaagtatcat gtggcgcttt 2400
tggaatatga tgagcagggt gtggtgacat gcgatgattg gagaagagta gctgtcagct 2460
ctgagctctg tgtttattcc gacatggcga aactcagaac tctgcgcaga ctgcttcgaa 2520

```

WO 00/63397

PCT/EP00/03521

acggagaacc gcatgtcagt agcgcaaagg ttgttcttgt ggacggagtt ccgggctgtg 2580  
ggaaaaccaa agaaattctt tccagggtta attttgatga agatctaatt ttagtacctg 2640  
ggaagcaagc cgcggaatg atcagaagac gtgcgaattc ctcagggtt attgtggcca 2700  
cgaaggacaa cgttaaaacc gttgattctt tcatgatgaa ttttgggaaa agcacacgct 2760  
gtcagttcaa gaggttattc attgatgaag ggttgatgtt gcatactggt tgtgttaatt 2820  
ttcttgtggc gatgtcattg tgcgaaattg catatgttta cggagacaca cagcagattc 2880  
catacatcaa tagagtttca ggattcccgt accccgccca ttttgccaaa ttggaagttg 2940  
acgaggtgga gacacgcaga actactctcc gttgtccagc cgatgtcaca cattatctga 3000  
acaggagata tgagggcttt gtcagagca cttcttcggt taaaaagtct gtttcgcagg 3060  
agatggtcgg cgagagccgc gtgatcaatc cgatctcaaa acccttgcat ggcaagatcc 3120  
tgacttttac ccaatcggat aaagaagctc tgctttcaag aggggtattca gatgttcaca 3180  
ctgtgcatga agtgcaaggc gagacatact ctgatgtttc actagttagg ttaacccta 3240  
caccagtctc catcattgca ggagacagcc cacatgtttt ggtcgattg tcaaggcaca 3300  
cctgttcgct caagtactac actgttgta tggatccttt agttagtatc attagagatc 3360  
tagagaaact tagctcgtac ttgtagata tgtataaggc cgatgcagga acacaatagc 3420  
aattacagat tgactcgggtg ttcaaagggt ccaatctttt tgttcgagcg ccaaagactg 3480  
gtgatatttc tgatatgcag ttttactatg ataagtgctt cccaggcaac agcaccatga 3540  
tgaataattt tgatgctgtt accatgaggt tgactgacat ttcattgaat gtcaaagatt 3600  
gcatattgga tatgtctaag tctgttgctg cgctaagga tcaaatcaaa ccactaatac 3660  
ctatggtacg aacggcggca gaaatgccac gccagactgg actattggaa aatttagtgg 3720  
cgatgattaa aaggaaactt aacgcacccg agttgtctgg catcattgat attgaaaata 3780  
ctgcatcttt agttgtagat aagttttttg atagttattt gcttaaagaa aaaagaaaac 3840  
caaataaaaa tgtttctttg ttcagtagag agtctctcaa tagatggta gaaaagcagg 3900  
aacaggtaac aataggccag ctgcgagatt ttgattttgt agatttgcca gcagttgatc 3960  
agtacagaca catgattaaa gcacaaccca agcaaaaatt ggacacttca atccaaacgg 4020  
agtaccggcg tttgcagacg atttgtgtacc attcaaaaaa gatcaatgca atatttgcc 4080  
cgttgttttag tgagcttact aggcaattac tggacagtggt tgattcgagc agatttttgt 4140  
ttttcacaag aaagacacca gcgcagattg aggtttctt cggagatctc gacagtcag 4200  
tgccgatgga tgtcttgagg ctggatatat caaaatacga caaatctcag aatgaattcc 4260  
actgtgcagt agaatacag atctggcgaa gattgggttt tgaagacttc ttgggagaag 4320  
tttggaacaa agggcataga aagaccaccc tcaaggatta taccgcaggt ataaaaactt 4380  
gcactctgga tcaagaaaag agcggggagc tcacgacgtt cattggaaac actgtgatca 4440  
ttgctgcatg tttggcctcg atgttccga tggagaaaat aatcaaagga gccttttgcg 4500  
gtgacgatag tctgtgttac tttccaaagg gttgtgagtt tccggatgtg caacactccg 4560  
cgaatcttat gtggaatttt gaagcaaaac tgtttaaaaa acagtatgga tacttttgcg 4620  
gaagatatgt aatacatcac gacagaggat gcattgtgta ttacgatccc cttaaagttga 4680  
tctcgaaact tgggtctaaa cacatcaagg attgggaaca cttggaggag ttcagaaggt 4740  
ctcttttgta tgttgcgtt tcgttgaaca attgtgcgta ttacacacag ttggacgacg 4800  
ctgtatggga ggttcataag accgcccctc cagggttcgtt tgtttataaa agtctggtga 4860  
agtattttgtc tgataaagtt ctttttagaa gtttgtttat agatggctct agttgttaaa 4920  
ggaaaagtga atatcaatga gtttatcgac ctgacaaaaa tggagaagat cttaccgctc 4980  
atgtttaccc ctgtaaagag tggtatgtgt tccaaagttg ataaaaaat ggttcagag 5040  
aatgagtcag tgcagaggt gaaccttctt aaaggagtt agcttattga tagtggatac 5100  
gtctgttttag ccggtttggt cgtcacgggc gagtggaaact tgctgacaa ttgcagagga 5160  
ggtgtgagcg tgtgtctggt ggacaaaagg atggaaagag ccgacgaggc cactctcgga 5220  
tcttactaca cagcagctgc aaagaaaaga tttcagttca aggtcgttcc caattatgct 5280  
ataaccaccc aggacgcgat gaaaaacgtc tggcaagttt tagttaatat tagaaatgtg 5340  
aagatgtcag cgggtttctg tccgctttct ctggagtttg tgtcgggtgtg tattgtttat 5400

WO 00/63397

PCT/EP00/03521

```

agaaataata taaaattagg tttgagagag aagattacaa acgtgagaga cggagggccc 5460
atggaactta cagaagaagt cgttgatgag ttcattggaag atgtccctat gtcgatcagg 5520
cttgcaaagt ttcgatctcg aaccggaaaa aagagtgatg tccgcaaagg gaaaaatagt 5580
agtaatgac ggtagtgcc gaacaagaac tatagaaatg ttaaggattt tggaggaatg 5640
agttttaaaa agaataattt aatcgatgat gattcggagg ctactgtcgc cgaatcggat 5700
tcgtttttaa tatgtcttac agtatcacta ctccatctca gttcgtgttc ttgtcatcag 5760
cgtgggcccga cccaatagag ttaattaatt tatgtactaa tgccttagga aatcagtttc 5820
aaacacaaca agctcgaact gtcgttcaaa gacaattcag tgagggtgtg aaaccttcac 5880
cacaagtaac tgtaggttc cctgacagtg actttaagggt gtacaggtag aatgcggtat 5940
tagaccgct agtcacagca ctgttaggtg cattcgacac tagaaataga ataatagaag 6000
ttgaaaatca ggcgaacccc acgactgccg aaacgttaga tgctactcgt agagtagacg 6060
acgcaacggt ggccataagg agcgcgataa ataattaat agtagaattg atcagaggaa 6120
ccgtagctta taatcgagc tctttcgaga gctctcttg tttggtttg accctctgtc 6180
ctgcaacttg aggtagtcaa gatgcataat aaataacgga ttgtgtccgt aatcacacgt 6240
gggtgcgtacg ataacgcata gtgtttttcc ctccacttaa atcgaagggt tgtgtcttg 6300
atcgcgcggtg tcaaatgtat atggttcata tacatccgca ggcacgtaat aaagcgagg 6360
gttcgaatcc cccggttacc cccggtagg gcca 6395

```

&lt;210&gt; 3

&lt;211&gt; 1245

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: cDNA copy of  
the nucleotide sequence of the genome of STNV-2

&lt;400&gt; 3

```

agtaaagaca ggaaacttta ccgactatca gaatgacaaa acgtcaaagc aaacaatcaa 60
accgcaagag cgttgcatca cagggtgcgtg gtattgttga gtcaatggct gaggcagaagc 120
gatttgcttt tcttacgaac accaaccacag tctactacagc aggtaccgtg atcaacctga 180
gcaacaacat cgtgcaagga gatgaccttg ttaatcgac cggagaccag attaagacca 240
tacaccagac tttattgact cgggtgtacag gaattacca cagccaaagc tttcggttca 300
tctggtttcg tgacaacacc aataggggga ctacaccggc tgtgactgag gtgttagaca 360
gtgctagtat aacatcccag tataacccca ctacgttcca gcaaaagagg ttcactgttt 420
tccaagattt catgttggat acctctatag ttggacgtgt gattgtccat cggactgccg 480
ttgataagaa acggcgtgag atattttaca acggtgctgc tttctgtagc gcgtcaaagt 540
gccccggtgc cacatttgta cttgtcattg gatcacatgc cactggacag tatgatgtga 600
cagccgagat tgtttatctg gacatgtaga ccatggatcat gatgatgata gtgaaggagc 660
ctgaaagatg cgtagctacc ctctggtgc acttctggt gcaaaagcaga accaaaggg 720
acgggtggtac ggaggacagt agtcctgaac tagtaaatca ggaccgggag aaaaccagct 780
gacggctaaa tccattccca ctagtgtatt agtggaaaga gggcccgct gaattgggg 840
ggctgcatgg ggtggaaaac catgtggctg cagtcatttc tctatgcat tattgtctca 900
atacttgtgt gcaacaatgc tgtaaatcaa cgtagcactc aacatcactt caaaaccccc 960
tccatgtcac aagaatcaag atgcatgtct gtgttttagc gtatatattt tgcattccact 1020
tgatcgtgat tttgccctgg gcacctcgcg cggttggtac ccgaggagac tccccacagc 1080
aacatggcat taggcaggga taaggtatag tgactagaca aatgcgcgtg aagctggaaa 1140
gtccgggttag cagtgggggt gtgcggaatg cagcctcaac aaggatatag tgctgcatag 1200

```

WO 00/63397

PCT/EP00/03521

gagatgtgaa ccttttcaaac ttgaattcaa gtctcatgac tgccc

1245

&lt;210&gt; 4

&lt;211&gt; 1058

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: cDNA copy of  
the nucleotide sequence of the genome of STMV

&lt;400&gt; 4

```
agtaaactta ccaatcaaaa gacctaacca acaggactgt cgtggtcatt tatgctgttg 60
ggggacatag ggggaaaaca tattgccttc ttctacaaga ggccttcagt cgccataatt 120
acttggcgcc caattttggg tttcagttgc tgtttccagc tatggggaga ggtaagggtta 180
aaccaaaaccg taaatcgacg ggtgacaatt cgaatgttgt tactatgatt agagctggaa 240
gctatcctaa ggtcaatccg actccaacgt gggtcagagc catacctttc gaagtgtcag 300
ttcaatctgg tattgctttt aaagtaccgg tcgggtcact attttcggca aatttcggga 360
cagattcctt tacaagcgtc acagtgatga gtgtccgtgc ttggaccag ttaacaccgc 420
cagtaaataga gtacagtttt gtgaggctga agccattggt caagactggt gactctactg 480
aggagttcga agggcgtgca tcaaacaatca acacacgagc ttctgtaggg tacaggattc 540
caactaattt gcgtcagaat actgtggcag ccgacaatgt atgcgaagta agaagcaact 600
gtcgacaagt cgccttggtt atttcgtgtt gttttaactg aacctcgaca taagcctttt 660
ggatcgaagg ttaaaccgatc cgctcctcgc ttgagcttga ggcggcgtat ctcttatgtc 720
aacagagaca ctttggtcta tggttgtata acaatagata gactcccgtt tgcaagatta 780
gggttaacag atcttgccgt tagtctggtt agcgcgtaac cggccttgat ttatggaata 840
gatccattgt ccaatggctt tgccaatgga acgcccagct ggctgtataa tacgtcgttg 900
acaagtacga aatcttggtt gtgtttttcc ctccacttaa atcgaagggt tttgttttgg 960
tcttcccga cgcatacgtt agtgtgacta ccgttggtcg aaacaagtaa aacaggaagg 1020
gggttcgaat ccctccctaa ccgcggttaa gcggccca 1058
```

&lt;210&gt; 5

&lt;211&gt; 6355

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: cDNA copy of  
the nucleotide sequence of the genome of TMV-U2

&lt;400&gt; 5

```
gatgttttaa tagttttcga caacaacaat taaaacaaaa acaacatatt acaaacaaca 60
aacaacaaca atggcacaca tacaatctat aattagcaac gcccttcttg aaagcgtgag 120
tggtaaaaac actctcgtta atgaccttgc aagaaggcgc atgtacgata cgcccggtgga 180
agaatttaac gccgcgaccc gtagacaaa ggtaacttt tccaaaacta ttagcgaaga 240
gcaaacgctt ctagtctcca acgcgtaccc ggagtccag attacctttt ataatactca 300
aatgcccgt cagagtttgg ctggaggtt gagagcatta gaattggaat atctgatgct 360
acaagtcccc tatggatcgc cgacatatga tataggtggg aactttgcag cacatttgtt 420
```

WO 00/63397

PCT/EP00/03521

caaaggcagg gattacgtgc attgctgtat gcccaatctg gacatacgag atataatgag 480  
gcacgaagga caaaaggact caattgagat gtatttgtcc agattgtctc gttctaacaa 540  
ggtaatcctt gagtttcaaa gggaggcttt taacaggatg gcagaagctc ccaacgaagt 600  
ctgctgctct aaaacttttc aggattgtcg aatacatccg ccagagaata gtggtagaag 660  
atacgctgtt gctctgcaca gtttgtatga ttttctgtg catgagtttg gagctgctt 720  
aatacttaag aatatacatg tatgttatgc agcttccatt ttggcagaag cattattact 780  
agaccagacg gaggttacgc ttaattgaaat aggcgcaact ttcaaaagag aagggtgatga 840  
tgtttctttt ttctttgtcg atgaaagtac tttaaattat agtcataaat acaaaaatat 900  
cttgacattat gtagttaaat cttactttcc tgcttctagt agaatagttt actttaagga 960  
atttttagtc actagggtta atacttggtt ttgtaaattt accaaagtag atacctatat 1020  
tctgtacaag agtggttagac aagtaggggtg tgatagtgat cagttctatg aggcgatgga 1080  
agacgccttt gcttacaaga aaacctggc catgttcaac actgaaagag caatcttttag 1140  
agacacggct tcgggttaact tttggttccc taagatgaag gacatgggtg tagtaccgct 1200  
gtttgaggggt tctattacca gcaaaaagat gacaaggagt gaggtcattg ttaatcgtga 1260  
cttcgtttac acagtgttta atcatatcag aacatatcaa gccaaagcgt taacttacca 1320  
gaacgtatta tctttcgtgg agtctataag atcccgcgtg ataataatg gtgttactgc 1380  
taggtctgaa tgggatgtag ataaagcaat tcttcaacct ttgtcaatga ctttcttctt 1440  
gcagactaag ctggctgcgc ttcaagacga tatagtaatg ggaaagtctt ggtgcttgga 1500  
taagaccact tctgaactta tttgggatga ggtgggcaaa ttttttgga acgttttccc 1560  
cactatcaaa gagagattgg tgagcaggaa aattctggat gtaagtgaag atgctctgaa 1620  
gatcaagatc ccagatctgt atgtcacatg gaaagacagg ttcgtagctg aatacaccaa 1680  
gtctgaggag ttaccgcacg tagatatcaa gaaggactta gaagaagctg agcaaagtga 1740  
cgacgcgtta tcagaattat ctatccttaa ggggtgctgat aatttcgata tcgcgaagt 1800  
caaagacatg tgcaaggctt tagatgttag tctgtatgtg gcagcacgag taatcgttgc 1860  
agtggccgag aatagaagcg gtttaactct tacttttgat aagccaaccg aggagaatgt 1920  
ggctaaggct cttaaaagca cggcgtctga ggccgtggtg tgtcttgaa cgcacatccga 1980  
agaggtgaac gtaataaaat tttctattgc tgagaaaggg agattgcctg tgtgtgcaga 2040  
aagtcattgt ttgacgaatg ctaacttaga gcaccaggag ttggagtccc tcaacgattt 2100  
ccataaggct tgcgtggata gtgtgattac aaagcaaatg gcatcggttg tctacactgg 2160  
ctcactcaaa gttcaacaaa tgaagaacta tgtggacagt ttggcagctt cgttgtccgc 2220  
cactgtatca aatctatgca agtactaaa ggatgaagtc gggatgatt ctgattccag 2280  
ggagaaagt tgggtttggg atgtcacttt gaaaaagtgg ctctcaaac ctgcccga 2340  
aggtcattca tggggagtgt tcttggtata caaggggaaa atgtttactg cacttctatc 2400  
ttatgaagga gatagaatgg tgactgagag cgactggagg aggggtggctg tatcatctga 2460  
tacaatggtg tattctgata ttgcaaagct ccaaaatctg aggaaaacaa tgagagacgg 2520  
tgaacccac gaacctactg caaagatggt acttggtggat ggggtgcctg gttgtggaaa 2580  
gtacaaagga gattttgaaa gatttgatct tgatgaggat ttgatcttgg ttcctggaaa 2640  
acaagctgct gctatgatca gaagaaggc taattcatct ggactgataa gagccacaat 2700  
ggacaatgtg agaacggtag attcacttct aatgcaccca aaaccgcgat cacacaagag 2760  
gctttttatt gatgaagggt tgatgtgca caccggttgt gtttaacttc tgggtgctt 2820  
ctctggttgc garatcgcat acatttacgg agatacacag cagattcctt tcattaacag 2880  
agttcagaat tccccgtatc ccaaactatt tgagaagctg caagtggatg aagttgagat 2940  
gaggaggacc aactgagat gccaggtga tgtgaatttt ttcctacaat cgaagtacga 3000  
aggagcgggtg acaaccactt caactgtaca acgatcggct tcatctgaga tgatagggcg 3060  
taaggagta ctaaacagt tttccaaacc actaaaaggg aaaattgtaa ctttactca 3120  
ggctgataaa tttgagttag aggagaaggg ctataagaat gtgaacaccg ttcattgagat 3180  
ccaaggagaa acctttgaag atgtgtcgtt ggtcagattg acggcaactc cactgactct 3240  
gatttccaag tcttccccgc atgttctagt cgctctgact agacacacaa agagcttcaa 3300

WO 00/63397

PCT/EP00/03521

atattacacc gtagtgtag atcctttagt acagataatt agtgatttgt cttctttaag 3360  
ctccttcctt ttagaaatgt atatggtaga agcaggtagt agatagcaat tacagatgga 3420  
tgcagtgttc aaagggtcata atctctttagt ggcaacacct aaatcaggag actttccaga 3480  
tctacagtgc tattacgatg tatgcctccc tggtaatagt actatactta acaagtatga 3540  
tgctgttacc atgagggttac gtgataatag tcttaatgtg aaggattgtg ttcttgattt 3600  
ttccaaaagt attccgatgc caaaggaggt gaaacctagt ctagagccag ttttgcgtag 3660  
cgccggcgaa ccgccaaggg ctgcaggact actcgaaaat ctggttgcaa tgattaaaaa 3720  
aaatttcaac gcaccagacc tgacggggac gattgacatt gagagcaccg catctgttgt 3780  
agtagataag ttttttgata gctattttat taaaaaagaa aaatacacia aaaatattgc 3840  
tggagtgtg acgaaggatt caatgatgag atggttgga aacaggaaag aagtactatt 3900  
ggacgacttg gctaactaca attttacaga tctgccggcc atcgatcagt acaagcacat 3960  
gatcaaggct caacaaaac agaaattgga ctttcaatt cagaatgaat accctgctct 4020  
gcaacaatt gtctaccatt cgaagcagat caacggtatt ttggccggtt tctcagagct 4080  
tacaagggtg ctgctcgagg catttgattc taagaagttt ctttcttta ctaggaaaac 4140  
tccagaacag attcaagaat ttttctcga tctcgactcg cacgttccta tggatgtgtt 4200  
agaactggat atttctaagt atgataagtc acagaacgag tttcattgtg ctgtagagta 4260  
tgaaatatgg aaaagattgg gtctcaatga gtttttgcc gaagtgtgga aacaaggga 4320  
caggaaaaca actttgaagg attacattgc tggatcaag acatgtctgt ggtatcaaag 4380  
gaaaagcggg gatgtgacta ctttcacgg caatactgtt ataatacgag cttgcttggg 4440  
ttcaatgta ccgatggaaa aggtcataaa aggtgctttt tggggagacg attccgtttt 4500  
gtattttcca aagggtttgg atttccctga cattcagtc tgtgctaate tcatgtggaa 4560  
tttgaggcc aaactgtata gaaagaggta cgggtacttt tgtggtagat acatcataca 4620  
ccatgataag ggagcaatag tgtattatga tctttgaag ttgatctcca aacttggggc 4680  
aaaacatac aaggattatg atcacttaga agagttagg gtgtcttgt gcgatgttgc 4740  
ttgttcgctc ggaaactggt gcttaggctt tccgcagctg aacgcagcta tcaaggaggt 4800  
tcataaaacc gcgattgatg gttcgtttgc ttttaattgt gttacaaat ttttgtgtga 4860  
taaaatttta tttagaactt tgtttttaa tggctgttag tctcagagat actgtcaaaa 4920  
ttagcgagtt cattgatctt tcgaaacagg atgagatact tccggcattc atgactaagg 4980  
tcaagagtgt tagaatatcg actgtggaca agattatggc tgttaagaat gatagtcttt 5040  
ctgatgtaga tttacttaaa ggtgttaagt tagttaagaa agggatgtg tgccttagctg 5100  
atttggtagt gtctggggag tggaaatctc cggataactg ccgtgggtgcg gtcagtgttt 5160  
gtattgtaga taagagaatg aaaaggagta aggaagcaac gctgggtgcg tatcacgccc 5220  
ctgcttgcaa aaagaatttt tcttttaagc taatccctaa ttattcaata acatccgagg 5280  
atgctgagaa gcaccctggt caagtgttag tgaatatcaa aggagtggct atggaagaag 5340  
gatactgtcc tttatctttg gagttcgttt caatttgtgt agtacataaa aataatgtaa 5400  
gaaaagggtt gagggaaactg attttgagtg tgacagacgg ctcgccaatt gaactcactg 5460  
aaaagggtgt tgaggagttc gtggatgaag taccaatggc tgtgaaactc gaaaagggtc 5520  
cggaatacaa aaaagaaatg gtaggtaata atgttaataa taagaaaata aataacagtg 5580  
gtaagaaggg ttttaaaatt gaggaattg aggataatgt aagtgatgac gagtctatcg 5640  
cgtcatcgag tacgttttaa tcaatatgcc ttatacaate aactctccga gccaatttgt 5700  
ttacttatct tccgcttacg cagatcctgt gcagctgac aatctgtgtg caaatgcatt 5760  
gggtaaccag tttcaaacgc acaagctag gacaacagtc caacagcaat ttgcggatgc 5820  
ctggaaacct gtgcctagta tgacagttag atttctgca tggatttct atgtgtatag 5880  
atataattcg acgcttgatc cgttgatcac ggcttatta aatagctttg atactagaaa 5940  
tagaataata gaggttgata atcaaccgc accgaatact actgaaatcg ttaacgcgac 6000  
tcagagggtg gacgatgcta ctgtagctat aagggttca atcaataatt tggctaata 6060  
actggttcgt ggaactggca tcttcaatca agcaggcttt gagactgcta gtggacttgt 6120  
ctggaccaca actccggcta ctagctatt gttgtgagat tttctaaaat aaagtcgctg 6180

WO 00/63397

PCT/EP00/03521

aagacttaaa attcaggggtg gctgatacca aaatcagcag tgggtgttcg tccacttaaa 6240  
 tataacgatt gtcatactcg gatccaacag ttaaaccatg tgatgggtga tactgtggta 6300  
 tggcgtaaaa catcgagag gttcgaatcc tcccctaacc gccggtagcg gccca 6355

&lt;210&gt; 6

&lt;211&gt; 2346

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequenc : nucleotide  
 sequence of the tomato phytoene desaturase (pds)  
 encoding cDNA

&lt;400&gt; 6

cttttactag ttatagcatt cggatatcttt ttctgggtaa ctgccaaacc accacaaatt 60  
 acaagtttcc atttaactct tcaacttcaa cccaaccaa tttatttcct taattgtgca 120  
 gaaccactcc ctatatcttc taggtgcttt cattcgttcc gaggtgaaga aagatttttg 180  
 tttctttgaa tgctttatgc cactcgttta acttctgagg tttgtggatc ttttaggcga 240  
 cttttttttt ttttgtatgt aaaatttggt tcataaatgc ttctcaacat aaatcttgac 300  
 aaagagaagg aattttacca agtatttagg ttcagaaatg gataattttc ttactgtgaa 360  
 atatccttat ggcaggtttt actgttattt ttcagtaaaa tgccctcaaat tggacttggt 420  
 tctgctgtta acttgagagt ccaaggtagt tcagcttata tttggagctc gaggtcgtct 480  
 tctttgggaa ctgaaagtcg agatgggtgc ttgcaaagga attcgttatg ttttgctggt 540  
 agcgaatcaa tgggtcataa gttaaagatt cgtactcccc atgccacgac cagaagattg 600  
 gtaaggact tggggccttt aaaggctcgt tgcattgatt atccaagacc agagctggac 660  
 aatacagtta actatttga ggctgcattt ttatcatcaa cgttccgtgc ttctccgcgc 720  
 ccaactaaac cattggagat tgttattgct ggtgcagggt tgggtgggtt gtctacagca 780  
 aaatatttgg cagatgctgg tcacaaaccg atactgctgg aggcaaggga tgttctaggt 840  
 ggaaaggtag ctgcatggaa agatgatgat ggagattggt acgagactgg tttgcatata 900  
 ttctttgggg cttaccctaa tttcagaac ctgtttggag aattagggat taacgatcga 960  
 ttgcaatgga aggaacattc aatgatattt gcaatgccaa gcaagccagg agaattcagc 1020  
 cgctttgatt tctccgaagc tttaccgcgt cctttaaatg gaatttttag catcttaaag 1080  
 aataacgaaa tgcttacatg gccagagaaa gtcaaatttg caattggact cttgccagca 1140  
 atgcttgagg ggcaatctta tgttgaagct caagatggga taagtgttaa ggactggatg 1200  
 agaaagcaag gtgtgccgga cagggtgaca gatgaggtgt tcattgctat gtcaaaggca 1260  
 ctcaacttta taaaccctga cgaactttca atgcagtgca ttttgatcgc attgaacagg 1320  
 tttcttcagg agaaacatgg ttcaaaaatg gccttttttag atggtaatcc tcctgagaga 1380  
 ctttgcatgc cgattgttga acacattgag tcaaaagggt gccaaagtcag actgaactca 1440  
 cgaataaaaa agattgagct gaatgaggat ggaagtgtca agagttttat actgagtgac 1500  
 ggtagtgcga tcgagggaga tgcttttgtg tttgccgctc cagtggatat tttcaagctt 1560  
 ctattgcctg aagactggaa agagattcca catttccaaa agttggagaa gttagtgcga 1620  
 gtacctgtga taaatgtaca tatatggttt gacagaaaac tgaagaacac atatgatcat 1680  
 ttgctcttca gcagaagctc actgctcagt gtgtatgctg acatgtctgt tacatgtaag 1740  
 gaatattaca accccaatca gtctatgttg gaattgggtt ttgcacctgc agaagagtgg 1800  
 atatctcgca gcgactcaga aattattgat gcaacgatga aggaactagc aacgcttttt 1860  
 cctgatgaaa tttcagcaga tcaaagcaa gcaaaaatat tgaggtacca tgttgtcaaa 1920  
 actccgaggt ctgtttataa aactgtgcca ggttgtgaac ccg-cggcc tttacaaaga 1980



WO 00/63397

PCT/EP00/03521

tccccaatag aggggtttta tttagccgt gactacacga aacagaaata cttggcttca 2040  
atggaaggcg ctgtcttatac aggaaagctt tgtgctcaag ctattgtaca ggattatgag 2100  
ttacttggtg gacgtagcca aaagaagttg tcggaagcaa gcgtagtta gctttgtggt 2160  
tattatttag cttctgtaca ctaaatttat gatgcaagaa gcgttgta caacatatag 2220  
aagaagagtg cgaggtgaag caagtaggag aaatgttagg aaagctccta tacaaaagga 2280  
tggcatgttg aagattagca tctttttaat cccaagtta aatataaagc atattttatg 2340  
gaattc - 2346

<210> 7

<211> 7096

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: nucleotide  
sequence of the tobacco nitrate reductase (nia-2)  
encoding cDNA

<400> 7

tacatacaag ggcgcgaata aactttttt aaagtaaag tatatgaact tgcaatgaaa 60  
gaggacctta acttgtttgt ctttggtgct ttctgcacaa ttcaccttaa cagccattt 120  
gagattgatt tagttagtta taacaattag ttaaatgctt gtgtaatttg aagaaaatat 180  
ctggacgtgc tcgctgaaaa cattatactc ctatataata gaaatacttt ctgaaaagtt 240  
ggtcttggtc aaaaacgtat aagagagttg gtcttctcat aaatagtcac tagctttctg 300  
attttttttc actttctata tcacgtaaat aggtactcaa atttgatatt tacaccaaac 360  
aaatgaaaat aggatatgtg ttttccatac gtataattat ctatcgtaac taatgataca 420  
tacatataca tataacctta ctttttgatt actaaaaatt taattatatt taatttgggt 480  
aaatatcaga tgccacaaaa catttaccta gccactgtt ttgactacta aaaatttaac 540  
tatgtttagc ttgggtaaat atcagatgtc actaaacatt ttacctagcc attcctccga 600  
aaagaaattg agaaggaaat tagagttagt ggagccataa taatgtttta tgtgaccata 660  
actcggtgaa aaccacggca agaataagaa acagctgtta aggctaacca acagctgcat 720  
atctttaagc catttgctat taccccaaca tcgcatcttc ctctgatccc gaccctacgg 780  
gcgtaaaaag tgtaaatcgt tagaattgtt ttatttattt tatgatgtca ctatttttta 840  
aaatcaaaat taaattgggg tgcgattttt tttgggtcct gcttatgtat agtatggcgc 900  
tatggaggca ctgagagagt ccgaaacgtt tctatataag gccacccac gcattcaca 960  
acttcgttcc caaacagaa aagaaaatca aatctcggag agagagagag agaaatattt 1020  
tgagagagaa atacagaaaa tctctcttcc tctcttccct ttttttcaa tccccattca 1080  
tattcttttt ttagaataat ctatggcggc atctgtcgaa aacaggcagt tcagtcacct 1140  
agaagccggg ttatcccggt ctttcaagcc ccggtctgat tccccgggtc gtggctgcaa 1200  
cttcccttcg cccaacagta ctaatttcca aaagaaacca aattccacca tttacctga 1260  
ttactcgtcg agtgaagacg acgatgatga tgacgaaaaa aatgagtacc ttcaaatgat 1320  
taaaaaaggg aattcagagt tagagccatc tgttcatgac actagggacg aaggtaccgc 1380  
tgataattgg attgaacgca acttttccat gattcgtctc accggaaagc atccatttaa 1440  
ctccgaacca ccgttgaacc ggctcatgca ccacggcttt atcacaccgg tcccacttca 1500  
ttacgttcgt aaccatggac cgggtcccaa gggcacgtgg gatgactgga ccgtggaagt 1560  
cacgggacta gtgaagcgtc ctatgaaatt cacaatggac cagttggtta acgaattccc 1620  
ttgtagagaa ttgcccgtta cgcttggttg tgcgtgcaat cgaaggaaag aacagaacat 1680  
ggttaaacia accattgggt tcaactgggg cggcgtgccc gtttcaacia cgatatggcg 1740

WO 00/63397

PCT/EP00/03521

cggggtaccc ctccgcgctt tgctaaaacg gtgcgggtgt tttagcaaga ataaaggggc 1800  
gcttaatgtt tgcttcgaag gagctgatgt gttgcccgga ggtggtggtt caaagtatgg 1860  
aaccagcatt aagaaggaat ttgcaatgga tccagcacga gatatcatcg tagcctacat 1920  
gcagaacgga gaaaaattgg caccgcacca cgggtttcca gtacgaatga taattccagg 1980  
attcattgga ggaagaatgg tgaaatggat aaagaggatt atagtcacca cccaagaatc 2040  
agacagctat tatcatttca aggacaatag agttcttctt ccccatgttg atgctgaact 2100  
tgcaaatacc gaaggtagct accgtaacta tttcaattta ttactecatt tgttccaatt 2160  
tatgtgaacc tatttctctt ttggtccgtt caaaaaagaa tgaacccttt ctaaatttgg 2220  
taacaattta gcttaaacctt acaacttcac ccttaatgag aaacttttat aaccacacaa 2280  
ataccctggg gccatttgg acttggttag gtcgacaaat tccaaaagtt ttattttttt 2340  
cttaaacctt gtgctcagtc aaacagggtt acgtaaattg aaacggagag agtatcattt 2400  
ttattaaggg gtataaatat attttaatta gttgagactt gcacatacaa gtaaaatatt 2460  
tcttagaata caaaatcaac tgaaagctta cttctaatta tatggttttg aattttcctt 2520  
tcaatgaagt aaataaaaag gaaacaatta tattcaacgc atgtaggtat atggctcctg 2580  
cattatctca aatcaaatgg tttaaagaca aaggactttg gaaacataga attgtcagct 2640  
ttatagttat ggagtactat attagttagc tgtttgcac tattcataat tggctctatct 2700  
gtgtgcagca tgggtgtaca agccagagta tatcatcaat gagcttaata ttaactctgt 2760  
cattacgacg ccgtgtcatg aagaaatttt gccaatatgc gcctggacga ctcagcgacc 2820  
ttacacgttg aggggctatt cttattcttg ttagtatttt tatattttcc gattttgctg 2880  
agaatatcat atttcttagt tttgtcgata catcgatcc tctaactctg acgttttact 2940  
tcgtccttat gcaccactt acgtccttac tttctcagac agtttattga tgaaaactac 3000  
ttactatttt cgaccgata gccacagct ctttaattaa atgtgatgtt ttgaaagaga 3060  
tattctctcc cgtctatttt aattaatttt tggctgtttt tatacgtggg aatctatttt 3120  
taacattaat taatatagaa atgaaccata ttaattattat taatttcttc attgaaaata 3180  
caacaaatac tcttcggctc ttactacaat gacaattttg aagaaaaata attaatcct 3240  
tcctaataac tgaaaaatca aatattgttg accataaaaa aaggtaaaaa aattaattaa 3300  
aatgaactgg agagagtaaa ttgaaaaata taattatagc actagtaatt aaagttatta 3360  
gatgtcttct ttaaaaagcg tgtgaaaact ttaagacga aatataatat gaattattac 3420  
taatacttag aaagtgtcaa taattggtag acaattttaa ctatatacta gttaaaaagt 3480  
ctgtcaatac aactattagt attggggatt agagagaata gtagtaaaat ggagtaattg 3540  
gacgcagag cttgggcatg ctgattgctg tcagcttgtt tgctaattgtg aaaaagaaaa 3600  
tagtaagaaa agccaacat ggttttgttt attttattat gtggtagtac acaaaaacct 3660  
ggggagcttt cctagtcttg aagagtcggt ctttggtagc acaaaattaa tagtatagta 3720  
taccaagtga atattaaatt caattgtcta aagcacgga tctttttgac tactttagtt 3780  
cctgcactt gggttgcctc aacaacaccc tttattgaat tattatagta atgttcaata 3840  
taatatacaa ttgaaaaaca ctctaagtgg tcactttata tggatctagt caatactatt 3900  
tcttctaaac aacgtgccta attacttccc actttccagt acatgaccac cattaagttt 3960  
aatttttgtc aattccttgt gcaattggcc cttcaaatga gcagaagtgt tacgtaggaa 4020  
aactaacctc agctactatt ataggagtaa acctgttagg aaaagatgct cgaggaaactg 4080  
acaaaacttg tagaataatt agccattgta ttgattgaaa tactgattgt gaacgtgtaa 4140  
caaacaggcg gagggaaaaa agtaacgcga gtagaagtga cgttggatgg aggagaaaca 4200  
tggaagtta gcacactaga tcaccagag aagccacca aatatggcaa gtactggtgt 4260  
tgggtctttt ggtcactcga ggttgagggt ttagacttgc tcagtgttaa agaaattgct 4320  
gttcgagctt gggatgagac cctcaatact caaccgaga agcttatttg gaacgtcatg 4380  
gtacgttcac tcttctttt acctttattt cttttaactt ctatatacta gcggtgtaaa 4440  
gttattttac accataagtt aacttaca aaatgtgtaac tatttatact acgagtgatg 4500  
agggcaagaa ggggtttaag tatttgacaa taaatgtaaa ccctgcaatt ttgttcctaa 4560  
ttttttatcc tttcaactct ttgtgattgc ttcattatct agattcacag agcacatgtg 4620

WO 00/63397

PCT/EP00/03521

```

ttcacatgcc aaaacaaaaa actacaaaca aaaaaacttt tcactagctt tagtctaaga 4680
ttcccccttt tttttttggg aggtgtgtgg tccatactcc atagatcaat tccagccact 4740
gacgtaccaa accctgaaga ttccctagtag ttatagcgac gtacaatcat ttcataattat 4800
gtaagcagag acgtgatcac atgaactaga tgtgaatacc acttgcccag tccaccaggt 4860
caattcatct agatgtgtaa atcttgacac cagcactggg tcacttttat aacactagca 4920
tttaacaaca tttcatcctt gaacattact tgggctaatt aataagtatt tttttttata 4980
tactctaaaa attgtaatta cataaatgaa tttaacttat acacgctgac aatgttacta 5040
attccacttt ttacggacgg ttatctatag aaatcattta ggtgaaacaa ttctcttaca 5100
ctatgatcag tgtagtaca taatggttat tacattttct aaatattgtg ctatggtgca 5160
atgttcaggg aatgatgaat aattgctggt tccgagtaaa gatgaatgtg tgcaagcctc 5220
acaagggaga gattggaata gtgtttgagc atccgactca acctggaac caatcaggtg 5280
gatggatggc gaaggagaga catttgaga tatcagcaga ggcacctcaa aactaaaga 5340
agagtatctc aactccattc atgaacacag cttccaagat gtactccatg tccgaggtca 5400
ggaaacacag ctctgctgac tctgcttggg tcatagtcca tggctatata tatgacgcca 5460
cgcgtttctt gaaagatcac cctggtggga ctgacagcat tctcatcaat gctggcactg 5520
attgactga ggaatttgat gcaattcatt ctgataaggc taagaagctc ttggaggatt 5580
tcaggattgg tgaactcata actactgggt acacctctga ctctcctggc aactccgtgc 5640
acggatcttc ttccttcagc agctttctag cacctattaa ggaacttgtt ccagcgaga 5700
ggagtgtggc cctaattcca agagagaaaa tcccatgcaa actcatcgac aagcaatcca 5760
tctcccatga tgtaggaaa tttcgatttg cattgccctc tgaggatcaa gtcttgggct 5820
tgctgttgg aaaacataac ttcctctgtg ccgttattga cgataagctc tgcatgcgcg 5880
cttacacgcc tactagcacg atcgatgagg tggggactct cgagttggtt gtcaagatat 5940
acttcaaagg aattcacctt aaattcccca atggagggca aatgtcacag tatcttgatt 6000
ctatgccgtt agggtcattt ctgcacgtga aagggtccatt aggtcacatt gaataccaag 6060
gaaagggaaa tttcttagtt catggcaaac agaagtttg cagaagttg gccatgatag 6120
caggtggaac aggaataact ccagtgtatc aagtcacgca ggcaattctg aaagatccag 6180
aagatgacac agaaatgtat gtggtgtatg ctaacagaa acagagatgat attttactta 6240
aggaagagct tgattcatgg gctgagaaaa ttccagagag ggttaaagtt tggtatgtgg 6300
ttcaggatcc tattaagaa ggatggaagt acagcattgg ttttattaca gaagccattt 6360
tgagagaaca tatccctgag ccatctcaca caacactggc tttggcttgt ggaccacctc 6420
ctatgattca atttgcgtt aatccaaact tggagaagat gggctatgac attaaggatt 6480
ccttattggt gttctaattt taaaaacaaa acaatatctg caggaataaa tttttttttt 6540
ccccctatca gttgtacata ttgtatttgg tttatcacc ccatgtacta cgtagtggtt 6600
gtagttctta catttttatt ttttagaatt tttttaacc ttaggatata aaggttttct 6660
cttccaacaa agtgattctt tagggaagaa atgtactgta ctgtactagt atgtctaagc 6720
cgaaagttgt aatgtttacc atgacaaatt gtattcaatt cctcatggaa tagtaacatt 6780
gtgttcatgt gtcttcctgt aagcgatctt caaaatatca atgtatatat atagtaattg 6840
caaaccattg ttccttttcc cgatgtagtt aactactctt tcttttagctt ctagtctctg 6900
gtgaatattt ttttttctat aactctttaa ttaatacggc cttaaataag agaaaagttt 6960
aaaccacgaa tatcattatg cagacgtata ggtaattaat ctactttttg aaaaaaatc 7020
tattttcttt atgtgggtct tcaaaataat attctagaac cttttgtata ttccctttta 7080
acttctattt agttttt

```

<210> 8

<211> 1839

<212> DNA

<213> Artificial Sequence

WO 00/63397

PCT/EP00/03521

&lt;220&gt;

<223> Description of Artificial Sequence: nucleotide  
sequence of the tobacco nitrite reductase (nir-1)  
encoding cDNA

&lt;400&gt; 8

```
tttctattaa atttctggca ctttcattgc caaatccagc tagattttcc aagaatgctg 60
tcaagctcca cgcaactccg ccgtctgtgg cagcgccgcc agctggtgct ccagagggtg 120
ctgctgagag gctagaaccc agagttgagg aaaaagatgg ttattggata ctcaaggagc 180
agtttagaaa aggcataaat cctcaagaaa aggtcaagat tgagaagcaa cctatgaagt 240
tgttcatgga aaatggtatt gaagagcttg ctaagatacc cattgaagag atagatcagt 300
ccaagcttac taaggatgat attgatgtta ggcttaagtg gcttggcctc ttccatagga 360
gaaagaacca atatgggagg ttcatgatga gattgaagct tccaaatgga gtaacaacga 420
gtgcacagac tcgatacttg gcgagtgtga taaggaaata cgggaaagaa ggatgtgctg 480
atattacaac gaggcaaaat tggcagattc gtggagttgt actgcctgat gtgcccgaga 540
tactaaaggg actagcagaa gttgggttga ccagtttgca gagtggcatg gacaatgtca 600
ggaatccagt aggaaatcct cttgctggaa ttgatccaga agaaatagta gacacagggc 660
cttacctaa tttgctctcc caatttatca ctggcaattc acgaggcaat cccgcagttt 720
ctaacttgcc aaggaagtgg aatccgtgag tagtaggctc tcatgatctt tatgaacatc 780
cccatatcaa cgtatctcgc tacatgcctg ccacgaaaga tggacgattt ggattcaacc 840
tgcttgtggg tgggttcttc agcgcaaaaa gatgtgatga ggcaattcct cttgatgcat 900
gggttccagc tgatgatgtt gttccggttt gcaaagcaat actggaagct tttagagatc 960
ttggtttcag agggaacaga cagaaatgta gaatgatgtg gttaatcgat gaactgggtg 1020
tagaaggatt cagggcagag gtcgagaaga gaatgccaca gcaagagcta gagagagcat 1080
ctccagagga cttggttcag aaacaatggg aaagaagaga ttatcttggg gtacatccac 1140
aaaaacaaga aggctacagc tttattggtc ttcacattcc agtgggtcgt gttcaagcag 1200
acgatatgga tgagctagct cgttttagctg atgagtatgg ttcaggagag atccggctta 1260
ctgtggaaca aaacattatt attccaaca ttgagaactc aaagattgag gcaactgctca 1320
aagagcctgt tctgagcaca ttttcacctg atccacctat tctcatgaaa ggttttagtg 1380
cttgtagctg taaccagttt tgtggacaag ccataatcga gactaaagct cgttccttga 1440
tgataactga agaggttcaa cggcaagttt ctttgacacg gccagtggag atgcaactgga 1500
caggctgcc gaatacgtgt gcacaagttc aagttgcgga cattggattc atgggatgcc 1560
tgactagaga taagaatgga aagactgtgg aaggcgccga tgttttctta ggaggcagaa 1620
tagggagtga ttcacatttg ggagaagtat ataagaaggc tgttccttgt gatgatttgg 1680
taccacttgt tgtggactta ctagttaaca actttggtgc agttccacga gaaagagaag 1740
aaacagaaga ctaataaaat ttagaatagt tgggtgattt gctgtgttca taacatgtaa 1800
tgtatgataa atcaatgcaa acatttctac ctacgtgag 1839
```

&lt;210&gt; 9.

&lt;211&gt; 1294

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: cDNA of the  
beta-1,3-glucanase of Nicotiana plumbagenifolia

&lt;400&gt; 9

WO 00/63397

PCT/EP00/03521

ttgctcttca aatggctgct attatactgc taggattgct tgtttccagc actgagatag 60  
taggagctca atcagtaggt gtttgctacg gaatgctggg caacaacttg ccaccagcat 120  
cacaagttgt acaactgtac aagtcaaaa acataagaag aatgaggctt tatgatccaa 180  
atcaagcagc tttacaggct ttaagaggct ccaacattga agttatgtta ggagttccca 240  
attcagatct caaaacatt gctgctaacc cctcaaatgc aaataattgg gtccagagga 300  
atgtcagaaa tttctggcca gccgttaaatt ttaggtacat tgccgttgga aatgaagtca 360  
gccctgtaac aggcacatct tcaactaccc gatatcttct tccggccatg aggaacattc 420  
ggaatgcgat ttcttcagca ggtttgcaa acaatatcaa agtctcaagt tctgtagaca 480  
tgacctgat tgggaactct ttccaccat cacagggttc gtttaggaac gacgttaggt 540  
cgttcattga tccgattatt gggtttgtaa ggcgcataaa ttcgccttta ctggttaaca 600  
tttatcctta ttttagctat gctggtaatc cgcgcgatat ttctctccc tatgctcttt 660  
tcaactgctc aaatgtggtg gtacaagatg gttcacttg atataaaaac ttatttgatg 720  
caatgtcggg tgctgtgtat gctgccctgt ctgagccgg agggggctcg atagagattg 780  
ttgtgtccga gagtggctgg ccatctgctg gcgcatttgc cgcgacaaca aacaatgcag 840  
caacttacta caagaactta attcagcatg ttaaagggg tagtccaaga aggcctaata 900  
aagtcattga gacctattta tttgctatgt ttgatgagaa taacaaaaac cctgaattgg 960  
agaaacattt tggactcttt tcccccaaca agcagcccaa atatccactc agctttgggt 1020  
tttcagatag atattgggac atttctgctg aaaataatgc tactgcagct tctctcataa 1080  
gtgagatgtg ataagagagt tctctttaa tatctttaca tggatggaaa acttagtacc 1140  
aataactaga ttgtttcttt ctttatgcaa tttcttgta atgagagact agtacttgct 1200  
ctctgtgtcc ttgtggagag taactagaga caaattaagc aaataacata aataattgag 1260  
tgttgattct gcaatgataa atagaaaaaa aaaa 1294

&lt;210&gt; 10

&lt;211&gt; 720

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: green  
fluorescent protein encoding regon

&lt;400&gt; 10

atggtgagca agggcgagga gctgttcacc ggggtggtgc ccatcctggt cgagctggac 60  
ggcgacgtaa acggccacaa gttcagcgtg tccggcgagg gcgagggcga tgccacctac 120  
ggcaagctga cctgaagtt catctgcacc accggcaagc tgcccgtgcc ctggcccacc 180  
ctcgtgacca cctgacctc cggcgtgcag tgcttcagcc gctaccccga ccacatgaag 240  
cagcacgact tcttcaagtc cgccatgccc gaaggctacg tccaggagcg caccatcttc 300  
ttcaaggacg acggcaacta caagaccgc gccgaggtga agttcgaggg cgacaccctg 360  
gtgaaccgca tcgagctgaa gggcatcgac ttcaaggagg acggcaacat cctggggcac 420  
aagctggagt acaactacaa cagccacaac gtctatatca tggccgacaa gcagaagaac 480  
ggcatcaagg tgaacttcaa gatccgccac aacatcgagg acggcagcgt gcagctcgcc 540  
gaccactacc agcagaacac cccatcgccg gacggccccg tgctgctgcc cgacaaccac 600  
tacctgagca ccagtcgcg cctgagcaaa gacccaacg agaagcgca tcacatggtc 660  
ctgctggagt tcgtgaccgc cgccgggatc actctcgga tggacgagct gtacaagtaa 720

&lt;210&gt; 11

&lt;211&gt; 1809

WO 00/63397

PCT/EP00/03521

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial

Sequence: beta-glucuronidase encoding region

&lt;400&gt; 11

```
atggtccgtc ctgtagaac cccaaccgt gaaatcaaaa aactcgacgg cctgtgggca 60
ttcagtcctgg atcgcgaaaa ctgtggaatt gatcagcgtt ggtgggaaag cgcgttacia 120
gaaagccggg caattgctgt gccaggcagt ttaacgata agttcgccga tgcagatatt 180
cgtaattatg cgggcaacgt ctggtatcag cgcgaagtct ttataccgaa aggttgggca 240
ggccagcgta tcgtgctgctg tttcgatgctg gtcactcatt acggcaaagt gtgggtcaat 300
aatcaggaag tgatggagca tcaggcgccg tatacgccat ttgaagccga tgtcacgccg 360
tatgttattg ccgggaaaaag tgtacgtatc accgtttgtg tgaacaacga actgaactgg 420
cagactatcc cgccgggaat ggtgattacc gacgaaaacg gcaagaaaaa gcagtcttac 480
ttccatgatt tctttaacta tgccggaatc catcgacgctg taatgctcta caccacgccg 540
aacacctggg tggacgatat caccgtggtg acgcatgtcg cgcaagactg taaccacgccg 600
tctgttgact ggcaggtggt ggccaatggt gatgtcagcg ttgaactgctg tgatgcggat 660
caacaggtgg ttgcaactgg acaaggcact agcgggactt tgcaagtggg gaatccgcac 720
ctctggcaac cgggtgaagg ttatctctat gaactgtgctg tcacagccaa aagccagaca 780
gagtgatgata tctaccgctc tcgcgtcgcc atccggtcag tggcagtgaa gggcgaaacag 840
ttcctgatta accacaaacc gttctacttt actggctttg gtcgtcatga agatgcggac 900
ttacgtggca aaggattcga taacgtgctg atggtgcacg accacgcatt aatggactgg 960
attggggcca actcctaccg tacctcgcat tacccttacg ctgaagagat gctcgactgg 1020
gcagatgaac atggcatcgt ggtgattgat gaaactgctg ctgtcggtt taacctctct 1080
ttaggcattg gtttcgaagc gggcaacaag ccgaaagaac tgtacagcga agaggcagtc 1140
aacggggaaa ctcagcaagc gcacttacag gcgattaaag agctgatagc gcgtgacaaa 1200
aaccacccaa gcgtggtgat gtggagtatt gccaacgaac cggatacccg tccgcaagtg 1260
cacgggaata tttcgccact ggcggaagca acgcgtaaac tcgacccgac gcgtccgata 1320
acctgcgtca atgtaatggt ctgacgacgt cacaccgata ccatcagcga tctctttgat 1380
gtgctgtgcc tgaaccgtta ttacggatgg tatgtccaaa gcggcgattt ggaaacggca 1440
gagaaggtag tggaaaaaga acttctggcc tggcaggaga aactgcatca gccgattatc 1500
atcaccgaat acggcgtgga tacgttagcc gggctgcact caatgtacac cgacatgtgg 1560
agtgaagagt atcagtgctg atggctggat atgtatcacc gcgtctttga tcgcgtcagc 1620
gccgtcgtcg gtgaacaggt atggaatttc gccgattttg cgacctcgca aggcattattg 1680
cggttggcg gtaacaagaa agggatcttc actcgcgacc gcaaaccgaa gtcggcggt 1740
ttctgctgc aaaaacgctg gactggcatg aacttcggtg aaaaaccgca gcaggagggc 1800
aaacaatga 1809
```

&lt;210&gt; 12

&lt;211&gt; 411

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: cDNA copy of  
part of the region of a TMV-U2 variant comprising

WO 00/63397

PCT/EP00/03521

the origin of assembly

<400> 12

```
ccctcgccaa ttgaactcac tgaaaaagtt gttgatgagt tcgtagatga agtaccgatg 60
gctgtgaaac tcgaaagggt ccggaaaaca aaaaagagag tggtaggtaa taatgttaat 120
aataagaaaa taaataatag tggtaagaag ggtttgaaag ttgaggaaat tgaggataat 180
gtaagtgatg acgagtcctat cgcgtcatcg agtacgtttt aatcaatatg ccttatacaa 240
tcaactctcc gagccaattt gtttacttaa gttccgctta tgcagatcct gtgcagctga 300
tcaatctgtg tacaaatgca ttaggtaacc agtttcaaac gcaacaagct aggacaacag 360
tccaacagca atttgcggtat gcctggaaac ctgtgcctag tatgacagtg a 411
```

<210> 13

<211> 198

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: cDNA copy of  
STMV leader region

<400> 13

```
agtaaaactt accaatcaaa agacctaac aacaggactg tcgtgggtcat ttatgctgtt 60
ggggggacata gggggaaaac atattgcctt cttctacaag aggccttcag tcgccataat 120
tacttgccgc ccaattttgg gtttcagttg ctgtttccag ctatggggag aggtaaggtt 180
aaaccaaacc gtaaatcg 198
```

<210> 14

<211> 455

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: cDNA copy of  
STMV trailer region

<400> 14

```
gacaagtcgc cttggttatt tcgtgttggt ttaactgaac ctcgacataa gccttttgga 60
tcgaagggtta aacgatccgc tcctcgcttg agcttgaggc ggcgtatctc ttatgtcaac 120
agagacactt tggctctatg ttgtataaca atagatagac tcccgtttgc aagattaggg 180
ttaacagatc ttgccgttag tctggttagc gcgtaaccgg ctttgattta tggaatagat 240
ccattgtcca atggccttgc caatggaacg ccgacgtggc tgtataatac gtcgttgaca 300
agtacgaaat cttgttagtg ttttccctc cacttaaadc gaagggtttt gttttgggtc 360
tcccgaacgc atacgttagt gtgactaccg ttgttcgaaa caagtaaaac aggaaggggg 420
ttcgaatccc tccctaaccg cgggtaagcg gccca 455
```

<210> 15

<211> 1971

<212> DNA

WO 00/63397

PCT/EP00/03521

## &lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: cDNA copy of  
part of the genome of a TMV-U1 variant, comprising  
MP and CP genes

&lt;400&gt; 15

```
ggaaacactg tgattatagc tgcattgttg gcctcgatgc ttccgatgga gaaaataatc 60
aaaggagcct tttgtggtga cgatagtctg ctgtacttcc caaagggttg tgagtttccg 120
gatgtgcaac actccgcgaa tcttatgttg aattttgaag caaaactgtt taaaaaacag 180
tatggatact tttgcggaag gtatgtaata catcacgaca gaggatgcat tgtgtattac 240
gatccccata agttgatctc gaaacttggg gctaaacaca tcaaggattg ggaacacttg 300
gaggagtcca gaaggctctc ttgtgatgtt gctgtttcgt tgaacaattg tgcgtattac 360
acacagttag acgacgctgt atgggaggtt cataagaccg cccctccagg ttcgtttgtt 420
tataaaagtc tggtagaagta tttgtctgat aaagttcttt ttagaagttt gtttatagat 480
ggctctagtt gttaaaggaa aagtgaatat caatgagttt atcgacctga caaaaatgga 540
gaagatctta ccgtcgatgt ttaccctgtt aaagagtgtc atgtgttcca aagttgataa 600
aataatggtt catgagaatg agtcattgtc agaggtaaac cttctcaaag gagttaagct 660
tattgatagt ggatacgtct gtttagccgg tttggtcgtc acgggcgagt ggaacttgcc 720
tgacaattgc agaggaggtg tgagcgtgtg tctgggtggc aaaaggatgg aaagagccga 780
cgaggccact ctcggatctt actacacagc agctgcaaag aaaagatttc agttcaaggt 840
cgttcccaat tatgtataaa ccaccagga cgcgatgaaa aacgtctggc aagttttagt 900
caatattaga aatgtaaaga tgtcagcggg tttctgtccg ctttctctgg agtttgtgtc 960
ggtgtgtatc gtttatagaa ataataaaa attaggtttg agagagaaga tcacaagtgt 1020
gagagatgga gggcccatgg aacttacaga agaagttgtt gatgagttca tggaagatgt 1080
ccctatgtca atcaggcttg caaagtttcg atctcgaacc ggaaaaaaga gtgatgtccg 1140
taaagggaaa attagtagta gtgatcggtc agcgccgaac aagaactata gaaatgttaa 1200
ggattttgga ggaatgagtt ttaaaaagaa taatttaatc gatgatgatt cggagactac 1260
tgtcgccgaa tcggattcgt tttaaatatg tcttacagta tcaactactc atctcagttc 1320
gtgttcttgt cagcagcgtg ggccgaccca atagagttaa ttaatttatg tactaatgcc 1380
ttaggaaatc agtttcaaac acaacaagct cgaactgtcg ttcaaagaca attcagttag 1440
gtgtggaaac cttcaccaca agtgactgtt aggttccctg acagtgactt taagggtgtc 1500
aggtacaatg cggattatga cccgctagtc acagcactgt taggtgcatt tgacactaga 1560
aatagaataa tagaagttga aaatcaggcg aacccacaaa ctgccgaaac gttagatgct 1620
actcgtagag tagacgacgc aacgggtggc ataaggagcg ctataaataa tttagtagta 1680
gaattgatca gaggaaccgg atcttataat cggagctctt tcgagagctc ttctggtttg 1740
gtttggaact ctggtcctgc aacttgaggt agtcaagatg cataataaat aacggattgt 1800
gtccgtaatc acacgtggtg cgtacgataa cgcatagtgt tttccctcc acttaaatcg 1860
aagggtgtg tcttggtatg cgcgggtcaa atgtatatg ttcataataa tccgcaggca 1920
cgtaataaag cgagggggtc gaatcccccc gttacccccg gtagggggcc a 1971
```